Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy

ABSTRACT

The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/688,489, filed Apr. 16, 2015, which is a continuation of U.S.application Ser. No. 12/294,843, filed Jun. 30, 2009, which is a U.S.National Stage of International Application Number PCT/EP2007/002662,filed internationally on Mar. 26, 2007 which claims the benefit ofEuropean Application Number 06384006.0, filed Mar. 27, 2006 and EuropeanApplication Number 06025476.0, filed Dec. 8, 2006. The relatedapplications are hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention refers to the use of sodium channel blockers suchas tetrodotoxin or saxitoxin, its analogues/derivatives as well as theiracceptable salts, for the production of a medicament for the treatmentof neuropathic pain resulting from chemotherapy.

BACKGROUND OF THE INVENTION

The treatment of pain conditions is of great importance in medicine.There is currently a world-wide need for additional pain therapy. Thepressing requirement for a specific treatment of pain conditions or aswell a treatment of specific pain conditions which is right for thepatient, which is to be understood as the successful and satisfactorytreatment of pain for the patients, is documented in the large number ofscientific works which have recently and over the years appeared in thefield of applied analgesics or on basic research on nociception.

PAIN is defined by the International Association for the Study of Pain(IASP) as “an unpleasant sensory and emotional experience associatedwith actual or potential tissue damage, or described in terms of suchdamage (IASP, Classification of chronic pain, 2^(nd) Edition, IASP Press(2002), 210). Even though pain is always subjective its causes orsyndromes can be classified. Especially neuropathic pain which in thepast years has developed into a major health problem in broad areas ofthe population needs a very specific treatment, especially consideringthat any treatment of neuropathic pain is extremely sensitive to thecauses behind the pain, be it the agent/disease ultimately causing it orthe mechanistic pathway over which it develops. So, in a majority ofcases a substance being able to treat one subtype of neuropathic pain isnot—or is at least not necessarily—able to treat other specific subtypesdue to the highly diverse nature of this generalized symptom calledneuropathic pain.

On the other hand cancer and the therapy thereof are one of the biggesthealth concerns in the world. Besides surgery and close to alwayssupplementing it chemotherapy is the method of choice for controlling orhelping patients struck by carcinomas.

Chemotherapy is the use of chemical substances to treat disease and inthe sense of this invention refers primarily to the use of cytotoxicdrugs (called chemotherapeutic drugs) to treat cancer. Chemotherapy incancer consists of a personalized combination of potent chemotherapydrugs, designed to slow rapid cancer tumor growth, shrink tumors, killcancer cells, and prevent the spread of cancer. The chemotherapeuticdrugs prevent cells from replicating in the typical, out-of-controlmanner in which cancer cells divide.

Peripheral neurotoxicity is a clinically significant complication orcancer chemotherapy. For several of the most effective drugs (e.g.taxanes, vincristine, cisplatin), neurotoxicity is dose-limiting andsometimes forces the termination of otherwise successful therapy(Polomano and Bennett, 2001). Since these drugs are the treatment ofchoice for a multitude of lymphoid end solid tumours, hundred ofthousands of patients each year are affected. Sensory abnormalities fromantineoplastic-evoked neurotoxicity range from mild paresthesiae ordysesthesiae in many patients to a chronic painful peripheral neuropathyin a subset (Quasthoff and Hartung, 2002). The occurrence and severityof the neuropathy is dependent on single dose intensity, duration oftreatment, cumulative dose, prior or concurrent treatment with otherneuropathic drugs and co-existing conditions such as diabetes andalcohol abuse (Alberts et al., 1995; Postma et al., 1995; Forsyth etal., 1997; Quasthoff and Hartung, 2002). Thus it is known that as aresult of Chemotherapy in a considerable number of cases neuropathicpain/allodynia/hyperalgesia develops. This is a very specific,development of symptoms coming from neurotoxicity of thechemotherapeutic drug and treatment of that is crucial for assuringquality of live for patients suffering these consequences ofchemotherapy.

Therefore, the objective of the present invention was to provide a newform of treatment for neuropathic pain/allodynia/hyperalgesia developingas a consequence of Chemotherapy.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a time-course of paclitaxel induced thermal hyperalgesia,cold-allodynia and mechanical allodynia in mice.

FIG. 2 shows a time-course of the effect of co-administration ofpaclitaxel and tetrodotoxin or paclitaxel and saline on latency to hindpaw withdrawal in the plantar test, the duration of hind pawlicking/biting in the acetone test and threshold force for hind pawwithdrawal in the Von Frey test.

FIG. 3 shows a time-course of the effect on the latency to hind pawwithdrawal (plantar test) of a single s.c. injection of tetrodotoxin orsaline in mice pretreated with paclitaxel or paclitaxel-vehicle.

FIG. 4 shows a time-course of the effect on the duration of hind pawlicking/biting (acetone test) of a single s.c. injection of tetrodotoxinor saline in mice pretreated with paclitaxel or paclitaxel-vehicle.

FIG. 5 shows a time-course of the effect on the threshold force for hindpaw withdrawal (Von Frey test) of a single s.c. injection oftetrodotoxin or saline in mice pre-treated with paclitaxel orpaclitaxel-vehicle.

FIG. 6 shows a time course of the development of allodynia andhyperalgesia after paclitaxel and paclitaxel vehicle control treatmentin the orofacial and paw region.

FIG. 7 shows the effect of a single injection of TTX on orofacialallodynia, paw allodynia and paw hyperalgesia.

FIG. 8 shows the effect of tetrodotoxin on the time course ofpaclitaxel-induced allodynia in control animals.

DESCRIPTION

It is surprising that administration of TTX is highly effective for thetreatment far neuropathic pain/allodynia/hyperalgesia developing afterChemotherapy.

Thus, the present invention relates to the use of sodium channelblockers such as TTX or STX, its analogues/derivatives, optionally inthe form of its racemate, pure stereoisomers, especially enantiomers ordiastereomers or in the form of mixtures of stereoisomers, especiallyenantiomers or diastereomers, in any suitable mixing ratio; in neutralform, in the form of an acid or base or in form of a salt, especially aphysiologically acceptable salt, or In form of a solvate, especially ahydrate for the production of a medicament for the treatment ofneuropathic pain developing as a consequence of Chemotherapy.

“Chemotherapy” in the sense of this invention is defined as the use of achemotherapeutic drug for the treatment of cancer or tumors or malignneoplasia respectively.

“Developing as a consequence of Chemotherapy” according to thisinvention is defined as a) developing after or with the initiating ofChemotherapy and b) thus coinciding with or following the use of achemotherapeutic drug. Therefore the symptom to be treated—in allscientific likelihood—is being caused by or is due to thetoxicity/cytotoxicity, especially the neurotoxicity, of thechemotherapeutic drug.

“Chemotherapeutic drugs” in the sense of this invention are compoundsused in chemotherapy, especially those working by impairing mitosis(cell division), effectively targeting fast-dividing cells. As thesedrugs cause damage to cells they are termed cytotoxic. Some drugs causecells to undergo apoptosis (so-called “cell suicide”). Especiallypreferred chemotherapeutic drugs in the sense of this invention aredrugs derived from platin, especially the platin-derivatives cisplatin,carboplatin and oxaliplatin; plant alkaloids and terpenes (terpenoids).

“Plant alkaloids” (and terpenoids) are alkoloids derived from plants andblock cell division by preventing microtubule function. Microtubules arevital for eta division and without them it can not occur. The mainexamples are vinca alkaloids and taxanes.

“Vinca alkaloids” bind to specific sites on tubulin, inhibiting theassembly of tubulin into microtubules (M phase of the cell cycle). Theyare derived from the Madagascar periwinkle, Catheranthus roseus(formerly known as Vinca rosea). The ulna alkaloids include:Vincristine, Vinblastine, Vinorelbine, Vindesine.

Taxanes are derived from the Pacific yew tree, Texus brevfolla. Taxanesenhance stability of microtubules, preventing the separation ofchromosomes during anaphase. Taxanes include: Paclitaxel end Docetaxel.

Below is a list of chemotherapeutic drugs (by their trademarks),including paclitaxel (Taxol®), Iressa, Gefintinib and Xyotax:

13-cis-Retinoic Acid, 2-CdA, 2-Chlorodeoxyadenosine, 5-fluorouracil6-FU, 6-Mercaptopurine, 6-MP, 6-TG 6-Thioguanine, Abraxane, Accutane®,Actinomycin-D, Adriamycin®, Adrucil®, Agrylin®, Ala-Cort®, Aldesleukin,Alemtuzumab, ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®,All-transretinoic add, Alpha interferon, Altretamine, Amethopterin,Arnifostine, Aminoglutethimide, Anagrelid, Anandron®, Anastrozole,Arabinosylcytosine, Ara-C, Aranesp®, Aredia®, Arimidex®, Aromasin®,Arranon®, Arsenic trioxide, Asparaginase, ATRA, Avastin®, Azacitidine,BCG, BCNU, Bevadzumab, Bexarotene, BEXXAR®, Bicalutamide, BiCNU,Blenoxane®, Bleomycin, Bortezomib, Busulfan, Busulfex®, C225, CalciumLeucovorin, Campath®, Camptosar®, Camptothecin-11, Capecitabine, Carac™,Carboplatin, Carmustine, Carmustine wafer, Casodex®, CC-5013, CCNU (o),CDDP (t), CeeNU (t), Cerubidine (t), cetuximab, Chlorambucil, Cisplatin,Citrovorum Factor, Cladribine, Cortisone, Cosmegen (t), CPT-11 (o),Cyclophosphamide, Cytadren (t), Cytarabine, Cytarabine liposomal,Cytosar-U (t), Cytoxan®, Dacarbazine, Dactinomycin, Darbepoetin alfa,Daunomycin, Daunorubicin, Daunorubicin hydrochloride (t), Daunorubicinliposomal, DaunoXome (t), Decadron, Delta-Cortef (t), Deltasone (t),Denileukin, diftitox, DepoCyt (t), Dexamethasone, Dexamethasone acetate,dexamethasone sodium phosphate, Dexasone (t), Dexrazoxane, CHAD (o), DIC(I), Diodex (t), Docetaxel, Doxil (t), Doxorubicin, Doxorubicinliposomal, Droxia (t), DTIC, DTIC-Dome (t), Duralone (t), Efudex (t),Eligard (t), Ellence (t), Eloxatin (t), Elspar (t), Emcyt (t),Epirubicin, Epoetin alfa, Erbitux, Erlotinib, Erwinia L-asparaginase(t), Estramustine, Ethyol, Etopophos (t), Etoposide, Etoposide phosphate(t), Eulexin (t), Evista (t), Exemestane, Fareston (t), Faslodex (t),Femara®, Filgrastim, Floxuridine, Fludara (t), Fludarabine, Fluoroplex(t), Fluorouracil, Fluorouracil (cream), Fluoxymesterone, Flutamide,Folinic Acid (o), FUDR (t), Fulvestrant, G-CSF (t), Gefitinib,Gemcitabine, Gemtuzumab ozogamicin, Gemzar (t), Gleevec™, Gliadel wafer(t), GM-CSF (o), Goserelin, granulocyte—colony stimulating factor (t),Granulocyte macrophage colony stimulating factor (o), Halotestin (t),Herceptin (t), Hexadrol (t), Hexalen (t), Hexemethylmalamine (t), HMM(t), Hycamtin (t), Hydrea (t), Hydrocort Acetate (t), Hydrocortisone,Hydrocortisone sodium phosphate, Hydrocortisone sodium succinate,Hydrocortone phosphate (t), Hydroxyurea, Ibritumomab, IbritumomabTiuxoten, Idamycin®, Idarubicin Ifex®, IFN-alpha, Ifosfamide, IL-11,IL-2, Imatinib mesylate, Imidazole Carboxamide, Interferon alfa,Interferon Alfa-2b (PEG conjugate) (o), Interleukin-2 (t),Interleukin-11 (o), Intron A® (interferon alfa-2b), Iressa®, Irintecan,Isotretinoin, Kidrolase (t), Lanacort (t), L-asparaginase (t), LCR (o),Lenalidomide, Letrozole, Leucovorin, Leukeran (t), Leukine (t),Leuprolide, Leurocristine (o), Leustatin (t), Liposomal Ara-C (t),Liquid Pred (t), Lomustine, (o), L-Sarcolysin (o), Lupron (t), LupronDepot (t), Matolane (t), Maxidex (t), Mechlorethamine, MechlorethamineHydrochloride, Medralone (t), Medrol®, Megace (t), Megestrol, MegestrolAcetate (o), Melphalan, Mercaptopurine, Mesna, Mesnex (t), Methotrexate,Methotrexate Sodium (o), Methylprednisolone, Meticorten (t), Mitomycin,Mitomycin-C (o), Mitoxantrone, M-Prednisol (t), MTC (o), MTX (o),Mustargen (t), Mustine, Mutamycin (t), Myleran (t), Mylocel (t),Mylotarg (t), Navelbine (t), Nelarabine, Neosar (t), Neulasta (t),Neumega (o), Neupogen (t), Nexavar®, Nilandron (t), Nilutamide, Nipent®,Nitrogen Mustard (o), Novaldex (t), Novantrone (t), Octreotide,Octreotide acetate (o), Oncospar (t), Oncovin (t), Ontak (t), Onxal (t),Oprevelkin, Orapred (t), Orasone (t), Oxaliplatin, Paclitaxel, PederastProtein-bound, Pamidronate, Panretin (t), Paraplatin (t), Pediapred (t),PEG Interferon, Pegaspargase, Pegfilgrastim, PEG-INTRON (t),PEG-L-asperaginase, PEMETREXED, Pentostatin, Phenylalanine Mustard (o),Platinol (t), Platinol AQ (t), Prednisolone, Prednisone, Prolone (t),Procarbazine, PROCRIT®, Proleukin Prolifeprospan 20 with CarmustineImplant (t), Purinethol (t), Reloxifene, Revlimid®, Rheumatrex (t),Rituxan (t), Rituximab, Roferon-A®, (interferon alfa-2a) Rubex (t),Rubidomycin hydrochloride (t), Sandostatin®, Sandostatin LAR (t),Sargramostim, Solu-Cortef (t), Solu-Medrol (t), Sorafenib, STI-571,Streptozocin, SU11248, Sunitinib, Sutent®, Tamoxifen, Tarceva®,Targretin (t), Taxol®, Taxotere (t), Temodar®, Temozolomide, Teniposide,TESPA (o), Thalidomide, Thalomid®, TheraCys (t), Thioguanine,Thioguanine Tabloid (t), Thiophosphoamide (o), Thioplex (t), Thiotepa,TICE®, Toposar (I), Topotecan, Toremifene, Tositumomab, Trastuzumab,Tretinoin, Trexall®, Trisenox (t), TSPA (o), VCR (o), Velban (t),Velcade®, VePesid (t), Vesanold (t), Viadur (t), Vidaza (t),Vinblastine, Vinblastine Sulfate (o), Vincasar Pfs (I), Vincristine,Vinorelbine, Vinorelbine tartrate (o), VLB (o), VM-26 (o), VP-16 (t),Vumon (t), Xeloda®, Xyotax, Zanosar (t), Zevelin™, Zinecard (t),Zoladex®, Zoledronic acid, Zomala®.

In addition there is another list of drugs used in cancer-therapy(mostly as chemotherapeutics):

(as trademarks): Aldara, Alimta, Androcur, Arimidex, Borea, Caelyx,Campto, Casodex, Decapeptyl, Eloxatin, Eutirox, Faslodex, Femora,Gemzar, Gonapeptyl, Griselin, Herceptin, Isovorin, Lysodren, Magefren,Metvix, Navelbine, Novaldex, Novantrone, Paraplatin, Procrin, Prostacur,Suprefect, Tamoxifene Funk, Taxol, Taxotere, Testex, Elmu/Prolongatum,Tomudex, Ulefos, Vepesid, Xeloda, Zoladex;

(as active compounds): Anastrozole, Bicalutamide, Busereline,Capecetabine, Cisplatin, Carboplatin, Desoxorubicin, Docetaxel,Etoposid, Fulvestrant, Gemcitabine, Gosereline, Irinotecan, Letrozole,Leuproreline, Megestrol, Mitotane, Mitoxantrone, Oxaliplatin,Paclitaxel, Pemetrexed, Ralitrexed, Tamoxiphen, Tegafur, Triptoreline,Vincristine, Vinblastine, Vinorelbine, Vindesine.

Paclitaxel (Taxol®) is one of the most effective and commonly usedantineoplastic drugs for the treatment of solid tumours. It has twoserious side effects, myelosupression and peripheral neurotoxicity.Granulocyte colony-stimulating factor effectively counteracts theneutropenia in most patients. Unfortunately, there are no acceptabletherapies to prevent or minimize the nerve damage, making neurotoxicitya significant dose-limiting side effect (Rowinsky et al., 1993a, b;Wasserhelt et al., 1996; Gordon et al., 1997). Paclitaxel-inducedneurotoxicity typically presents as a sensory neuropathy, with the mostcommon complaints being numbness, tingling, burning pain and coldallodynia (Rowinsky et al., 1993a; Chaudhry et al., 1994; Forsyth etal., 1997; Dougherty et al., 2004). Sensory symptoms usually startsymmetrically in the feet, but sometimes appear simultaneously in bothhands and feet (Rowinsky et al., 1993a; Quasthoff and Hartung, 2002). Aclinically significant number of patients with paclitaxel-Inducedneuropathy experience neuropathic pain. For example, in a study of 27patients treated with pacilitaxel doses of 135, 175 and 250-300 mg/m²,neuropathic symptoms occurred in 60, 79 and 100% of patients,progressing to dose-limiting neurotoxicity in 0, 21 and 71% of patients,respectively (Postma at al., 1995).

“Neuropathic pain” is defined by the IASP as “pain initiated or causedby a primary lesion or dysfunction in the nervous system” (IASP,Classification of chronic pain, 2^(nd) Edition, IASP Press (2002), 210).For the purpose of this invention included under this heading or to betreated as synonymous is “Neurogenic Pain” which is defined by the IASPas “pain initiated or caused by a primary lesion, dysfunction ortransitory perturbation in the peripheral or central nervous system”. Inregards to this invention the neuropathic pain treated according to thisinvention is restricted to the neuropathic pain resulting fromchemotherapy, meaning being caused by the use of a chemotherapeutic drugin chemotherapy. The most likely cause of this is neurotoxicity of thechemotherapeutic drug, especially peripheral neurotoxicity.

Neurotoxicity of the chemotherapeutic drug often leads to sensoryneuropathy, which i.a. results in burning pain and/or cold allodynia,especially cold allodynia.

The term “analogues” as used in this application is defined here asmeaning a chemical compound that is a derivative of a compound which hassimilar biochemical activity to that compound. For example “Analogues”of TTX bind to the same site on the alpha subunit of sodium channels asdoes TTX.

The term “derivatives” as used in this application is defined here asmeaning a chemical compound having undergone a chemical derivation suchas substitution or addition of a further chemical group to change (forpharmaceutical use) any of its physico-chemical properties, such assolubility or bioavailability. Derivatives include so-called prodrugs,e.g. ester and ether derivatives of an active compound that yield theactive compound per ee after administration to a subject.

Examples of well known methods of producing a prodrug of a given actingcompound are known to those skilled in the an and can be round e.g. inKrogsgaard-Larsen et al., Textbook of Drug design and Discovery, Taylor& Francis (April 2002).

“Sodium channel blockers” or “sodium channel blocking compounds”encompass any chemicals that bind selectively to a sodium channel andthereby deactivate the sodium channel. In particular they includechemicals which bind to the SS1 or SS2 extracellular domains of en alphasubunit of a sodium channel. Sodium channel blocking compounds that bindto the SS1 or SS2 subunit of a sodium channel, particularly tetrodotoxinand saxitoxin, are found to possess similar pharmaceutical activity(U.S. Pat. No. 6,407,088, hereby incorporated by reference).

Tetrodotoxin (alternatively in the context of this applicationabbreviated TTX), also known as Ti Qu Duo Xin, is an alkaloid found inpuffer fish (Tetradontiae). The chemical name isOctahydro-12-(Hydroxymethyl)-2-imino-5, 9, 7,10a-dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentolwith a molecular formula C₁₁H₁₇N₃O₈ and a Molecular weight of 319.27. Itis a potent non-protein neurotoxin and an indispensable tool for thestudy of neurobiology and physiology. Tetrodotoxin (TTX) is a marineorganic toxin which is mainly found in testicles, ovaries, eggs, livers,spleens, eyeballs, end blood of puffer fish as wets as in diverse animalspecies, including goby fish, newt, frogs and the blue ringed octopusand even in marine alga. Several processes for producing TTX are known.Usually fix is extracted from marine organisms (e.g. JP 270719 Goto andTakahashi) but besides numerous others methods of synthesis are alsodescribed (and used for the preparation of tetrodotoxin in connection tothis invention) in U.S. Pat. Nos. 6,552,191, 6,478,966, 6,562,968 or2002/0086997, all of which are included here by reference. Tetrodotoxinis a well known compound described for example in WO02/22129 assystemically acting as analgesic. For one of the many descriptions ofTTX it is recommended turn to e.g. Tu, Anthony (Ed.) Handbook of NaturalToxins, Vol. 3: Marine Toxins and Venoms, 1988, 185-210 as well as Kao(1968), Pharmacol. Rev, 18:997-1049 and others.

The phrase “its (tetrodoxin's) derivatives” according to this inventionis defined—using the definition of U.S. Pat. No. 6,030,974 (includedhere by reference)—as meaning amino perhydroquinazoline compounds havingthe molecular formula C₁₁H₁₇N₃O₈. “Tetrodoxin's derivatives” accordingto this invention encompasses compounds described in U.S. Pat. No.5,846,975 (Included here by reference) as amino hydrogenatedquinazolines and derivatives including the substances set forth fromcolumn 3 line 40 to column 6 line 40. Specifically exemplified“derivatives of tetrodotoxin” according to this invention are includingbut are not limited to anhydro-tetrodotoxin, tetrodaminotoxin,methoxytetrodotoxin, ethoxytetrodotoxin, deoxytetrodotoxin andtetrodonic acid, 6 epi-tetrodotoxin, 11-deoxytetrodotoxin as well as thehemilactal type TTX derivatives (e.g. 4-epi-TTX, 6-epi-TTX,11-deoxy-TTX, 4-epi-11-deoxy-TTX, TTX-6-O-hemisuccinate, chiriquitoxin,11-nor-TTX-6(S)-ol, 11-nor-TTX-6(R)-ol, 11-nor-TTX-6,6-diol, 11-oxo-TTXand TTX-11-carboxylic acid), the lactone type TTX derivatives (e.g.6-epi-TTX (lactone), 11-deoxy-TTX (lactone), 11-nor-TTX-6(S)-ol(lactone), 11-nor-TTX-6(R)-ol (lactone), 11-nor-TTX-6,6-diol (lactone),5-deoxy-TTX, 5,11-dideoxy-TTX, 4-epi-6,11-didroxy-TTX,1-hydroxy-5,11-dideoxy-TTX, 5,6,11-trideoxy-TTX and4-epi-5,6,11-trideoxy-TTX) and the 4,9-anhydro type TTX analogs (e.g.4,9-anhydro-TTX, 4,9-anhydro-6-epi-TTX, 4,9-anhydro-11-deoxy-TTX,4,9-anhydro-TTX-8-O-hemisuccinate, 4,9-anhydro-TTX-11-O-hemisuccinate),The typical derivatives of TTX possess only ⅛ to 1/40 of the toxicity ofTTX in mice, based upon bioassay in mice. It has been observed thatthese derivatives produce joint action, and do not interact adversely.Examples of TTX derivatives include novel TTX derivatives isolated fromvarious organisms, as well as those that are partially or totallychemically synthesized (see e.g., Yotsu, M. et al. Agric. Biol. Chem.,53(3):893-895 (1989)).

“Derivatives and analogues of TTX”, as referred to in the presentinvention, may include compounds having the general formula I

wherein, R₂ and R₅ can be selected from the group consisting of H, OH,OAC, respectively;

R₁ call be H, or an alkyl with C₁-C₄, OH, OR, OC(O)R′, NH₂, NHR″,NR″R′″, among them R can be an alkyl with C₁-C₈, R′ can be an alkyl withC₁-C₃, and R″, R′″ can be an alkyl with C₁-C₄, respectively;

R₃ and R₄ can be ═O, or

when R₃ is H, R₄ can be selected from the group consisting of:

—ROH, and R is a branched or straight chain alkyl with C₁-C₇,

—CH(OH)NHOMe,

-NAP-gly,

-NAP-en,

—CH₂NH₂,

—CH₂NHCH₃,

-AAG,

-NMAG, and

-ANT;

when R₃ is OH or OC(O)R and R is an alkyl with C₁-C₃, R₄ can be selectedfrom the group consisting of:

—CHO,

—CH₂-gly,

—CH₂-β-Ala,

—CH₂-Lys,

—CH₂-en,

—CH₂-NAP-Lys

—CH₂-NAP-en,

—CH(OH)CH(NH₂)COOH; and,

—NH(CH₂)_(n)COOH,

—NH(CH₂)_(n)NH₂; and

—NH(CH₂)_(n)CH(NH₂)COOK

wherein:

n=1-6.

en is ethylene;

NAP is 4-triazo-2-nitrobenzoic amide, indicated as formula (a);

AAG is 2-triazo-O-aminobenzoic amide, indicated as formula (b);

NMAG is O-methylaminobenzoic amide, indicated as formula (c);

ANT is O-aminobenzoic amide, indicated as formula (d);

Among them, three kinds of compounds with the general formula II, III,IV are alternative.

The amino hydrogenated quinazoline compounds and derivatives thereof arecompounds having following general formula II,

wherein: R₁ can be selected from the group consisting of OH, an alkyl ora oxyalkyl with C₁-C₄, NH₂, NHR″, NR″R′″, among them R″ and R′″ can bean alkyl with C₁-C₄.

Among them, the more preferred compounds ere:

Tetrodotoxin R₁═OH (1);

-   -   deoxytetrodotoxin R₁═H (2);

The amino hydrogenated quinlazoline compounds and derivatives thereofare compounds having following general formula III

wherein:

R₃, R₄ are ═O, or

when R₃ is H, R₄ is selected from the group consisting of:

CH₂OH,

CH(OH)NHOMe,

-NAP-gly,

-   -   -NAP-en,

—CH₂NH₂,

—CH₂NHCH₃,

-AAG,

-NMAG, and

-ANT.

Among them, the more preferred compounds are:

AAG-degradation Tetrodotoxin R₄=AAG (3);

NMAG-degradation Tetrodotoxin R₄=NMAG (4);

ANT-degradation Tetrodotoxin R₄=ANT (5); and,

degradation Tetrodotoxin R₃, R₄ is ═O (6).

The amino hydrogenated quinazoline and their derivatives are compoundshaving following general formula IV;

wherein, R₄ can be selected from the group consisting of:

—CHO,

—CH₂-Gly,

—CH₂-β-Ala,

—CH₂-Lys,

—CH₂-en,

—CH₂-NAP-Lys,

—CH₂-NAP-en,

—CH(OH)CH(NH₂)COOH;

—NH(CH₂)₄CH(NH₂)COOH;

—NHCH₂COOH;

—NHCH₂CH₂COOH; and

—NHCH₂CH₂NH₂.

Among them, the more preferred compounds are;

oxytetrodotoxin R₄═CHO (7);

chiriquitoxin R₄═CH(OH)CH(NH₂)COOH (8);

and the compounds with the substituted groups of R₄:

—NH(CH₂)₄ CH(NH₂)COOH (9);

—NHCH₂COOH (10);

—NHCH₂CH₂COOH (11); and,

—NHCH₂ CH₂ NH₂ (12).

Preferably, the derivatives/analogues of tetrodotoxin comprisetetrodotoxin, anhydro-tetrodotoxin, tetrodaminotoxin,methoxytetrodotoxin, ethoxytetrodotoxin, deoxytetrodotoxin,epi-tetrodotoxin and tetrodonic acid, more preferably thederivatives/analogues of tetrodotoxin a consisting of tetrodotoxin,anhydro-tetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin,ethoxytetrodotoxin, deoxytetrodotoxin, epi-tetrodotoxin (4- and6-epi-tetrodotoxin) and tetrodonic acid.

Saxitoxin (STX) end its pharmacologically acceptable salts are speciesof 2,6-diamino-4-((aminocarbonyl)oxy) methyl-3a,4,8,9-tetrahydro-1H,10H-pyrrolo(1,2-a) purine-10,10-diol (3a5-(3a-a-a-4-a,10aR*)). Themolecular formula of Saxitoxin is C₁₀H₁₇N₇O₄, it has a molecular weightof 299.3 and a general structure of:

This, and its derivatives and its analogues may be used in accordancewith the disclosure. Saxitoxin is readily soluble in water and can bedispersed in aerosols. It is toxic by ingestion and by inhalation, withinhalation leading to rapid respiratory collapse and death. Chemically,saxitoxin is stable, although it can be inactivated by treatment withstrong alkali. It is naturally-occurring, produced by bacteria that growin other organisms, including the dinoflagellates Gonyaulax catenellaand G. tamarensis; which are consumed by the Alaskan butter clamSaxidomus giganteus and the California sea mussel, Mytituscalifornianeus. The toxin can be isolated from S. giganteus or M.californianeus. The first synthesis of STX was completed by Kishi andco-workers at Harvard in 1977 (J. Am. Chem. Soc. 1977, 99, 2818). Asecond synthesis was carried out by Jacobi and his collaborators whilstat Wesleyan University, Connecticut (J. Am. Chem. Soc. 1984, 106, 5594).A range of alternative methods for the synthesis and purification ofsaxitoxin will be apparent to those skilled in the art. Analogues andderivatives of saxitoxin include but are not limited to neosaxitoxin andanhydrosaxitoxin, any other biologically active variants of the abovesaxitoxin structure, and pharmaceutically acceptable salts thereof.

It will be appreciated that for the purposes set out herein,tetrodotoxin, saxitoxin, and their derivatives or analogues ormetabolite, can be optionally in the form of their racemate, purestereoisomers, especially enantiomers or diastereomers or in the form ofmixtures of stereoisomers, especially enantiomers or diastereomers, inany suitable ratio; in neutral form, in the form of an acid or base orin form of a salt, especially a physiologically acceptable salt, or inform of a solvate, especially a hydrate.

In this application “about” means “approximately,” end illustratively,the use of the term “about” indicates that dosages slightly outside thecited ranges may also be effective and safe, and such dosages are alsoencompassed by the scope of the present claims.

Compounds that are “administered together with TTX” or “in combinationwith TTX” may be administered as part of the same composition, or may beadministered separately, at the same or at separate times, in the sametherapeutic regimen.

In connection with this invention “neutral form” refers either to anon-Ionic form or to a neutrally net charged form, for example aZwitter-Ion at its isoelectric point.

The term “salt” according to this invention is to be understood asmeaning any form of the active compound according to the invention inwhich this compound assumes an ionic form or is charged and—ifapplicable—is also coupled with a counter-ion (a cation or anion). Bythis are also to be understood complexes of the active compound withother molecules end ions, in particular complexes which are complexedvia ionic interactions. As preferred examples of salts this includes theacetate, mono-trifluoracetate, acetate ester salt, citrate, formate,picrate, hydrobromide, monohydrobromide, monohydrochloride orhydrochloride.

The term “physiologically acceptable salt” in the context of thisinvention is understood as meaning a “salt” (as defined above) of atleast one of the compounds according to the invention which arephysiologically tolerated by humans and/or mammals.

The teen “solvate” according to this invention is to be understood asmeaning any form of the active compound according to the invention whichhas another molecule (most likely a polar solvent) attached to it vianon-covalent bonding. Examples of solvates include hydrates andalcoholates, e.g. methanolate.

The term “treatment” or “to treat” in the context of this specificationmeans administration of a compound or formulation according to theinvention to prevent, ameliorate or eliminate one or more symptomsassociated with neuropathic pain, hyperalgesia and/or allodynia.

Furthermore, the terms “to treat” or “treatment” according to thisinvention include the treatment of symptoms of neuropathic pain,hyperalgesia and/or allodynia, the prevention or the prophylaxis of thesymptoms of neuropathic pain, hyperalgesia and/or allodynia, theprevention or prophylaxis causing the symptoms of neuropathic pain,hyperalgesia and/or allodynia, as well as the prevention or theprophylaxis of the consequences causing the symptoms.

According to the various embodiments, the sodium channel blockers suchas TTX or STX, their analogues/derivatives or the pharmaceuticalcompositions comprising them, may be administered. In unit dosage form,intestinally, enterally, parenterally or topically, orally,subcutaneously, intranasally, by inhalation, by oral absorption,intravenously, intramuscularly, percutaneously, intraperitoneally,rectally, intravaginally, transdermally, sublingually, buccally, orallytransmucosally, Administrative dosage forms may include the following:tablets, capsules, dragees, lozenges, patches, pastilles, gels, pastes,drops, aerosols, pills, powders, liquors, suspensions, emulsions,granules, ointments, creams, suppositories, freeze-dried injections,injectable compositions. In food supplements, nutritional and food bare,syrups, drinks, liquids, cordials etc, which could be regularpreparation, delayed-released preparation, controlled-releasedpreparation and various micro-granule delivery system, u foodsupplements, nutritional and food bars, syrups, drinks, liquids,cordials. In case of tablet, various carriers known in the art may beused, e.g. dilutent and resorbent such as starch, dextrin, calciumsulfate, kaolin, microcrystalline cellulose, aluminium silicate, etc;wetting agent and adhesives such as water, glycerin, polyethyleneglycol, ethanol, propanol, starch mucilage, dextrin, syrup, honey,glucose solution, acacia, gelatin, carboxymethylcellulose sodium,shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone,etc; disintegrating agent, such as dried starch, alginate, agar powder,laminaran, sodium bicarbonate and citric acid, calcium carbonate,polyoxyethylene sorbitol aliphatic ester, lauryl sodium sulfate,methylcellulose, ethylcellulose, lactose, sucrose, maltose, mannitol,fructose, various disaccharides and polysaccharides etc; disintegrationinhibiting agent, such as sucrose, tristearin, cacao butter,hydrogenated oil, etc; absorption accelerator, such as quaternaryammonium salt, lauryl sodium sulfate, etc; lubricant, such as talc,silica, corn starch, stearate, boric acid, fluid wax, polyethylene, etc.The tablet may be further formulated into coated tablet, e.g.sugar-coated tablet, film-coated tablet, enteric-coated tablet, ordouble-layer tablet and multi-layer tablet. In the case of pill, variouscarriers known in the art may be used, e.g. dilutent and resorbent, suchas glucose, lactose, starch, cacao butter, hydrogenated vegetable oil,polyvinylpyrrolidone, kaolin, talc, etc; adhesives, such as acacla,bessora gum, gelatin, ethanol, honey, liquid sugar, rice paste or flourpaste, etc; disintegrating agent, such as agar powder, dried starch,alginate, lauryl sodium sulfate, methylcellulose, ethylcellulose. Incase of suppository, various carriers known in the art may be used, e.g.polyethylene, lecithin, cacao butter, higher alcohols, esters of higheralcohols, gelatin, semi-synthetic glyceride, etc. In the case ofcapsule, it may be prepared by mixing said sodium channel blockers asactive ingredient with the above mentioned carriers, followed by placingthe mixture into a hard gelatin capsule or soft capsule. Also, saidsodium channel blockers may be applied in the following dosage forms:microcapsules, suspension in an aqueous phase, hard capsule, orinjection. In the case of injection, such as liquor, emulsion,freeze-dried injection, and suspension, ail the dilutents common in theart may be used, e.g. water, ethanol, polyethylene glycol, propyleneglycol, oxyethylated isostearyl alcohol, polyoxidated isostearylalcohol, polyoxyethylene sorbitol aliphatic ester, etc. In addition, inorder to obtain isotonic injection, a suitable amount of sodiumchloride, glucose or glycerin may be added into the preparation, as wellas regular cosolvent, buffer, pH adjusting agent, etc. In addition,coloring agent, antiseptic, perfume, correctives, food sweetening agentor other materials may be added to the pharmaceutical preparation ifnecessary.

In certain embodiments a formulation or pharmaceutical compositionaccording to the invention contains the active ingredient (TTX, itsderivatives and/or its analogues) as well as optionally et least oneauxiliary material and/or additive and/or optionally another activeingredient.

In certain embodiments the auxiliary material and/or additive can bespecifically selected from conserving agents, emulsifiers and/orcarriers for parenteral application. The selection of these auxiliarymaterials and/or additives and of the amounts to be used depends uponhow the pharmaceutical composition is to be applied. Examples includehere especially parenteral like intravenous subcutaneous orintramuscular application formulations but which could also be used forother administration routes.

In certain embodiments routes of administration of tetrodotoxin itsderivatives and its analogues can include intramuscular injection,intraveneous injection, subcutaneous injection, sublingual, buccal,patch through skin, oral ingestion, implantable osmotic pump, collagenimplants, aerosols or suppository.

In alternative embodiments the sodium channel blockers such as TTX orSTX, their analogues/derivatives may be administered in a schedule ofone, two, three, four, five, six, seven, eight, nine, ten, eleven,twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen,nineteen, twenty or more doses per day, alone or in combination withother medications, over range of time periods including but not limitedto periods of one, two, three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, sixteen, eighteen, twenty, twentyfour, thirty, or more days; or over a period of one, two, three, four,five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen,sixteen, eighteen, twenty, twenty four, thirty, thirty six, forty eight,sixty, seventy two, eighty four or more months.

In particular embodiments the sodium channel blockers such as TTX orSTX, their analogues/derivatives may be a voltage-gated sodium channelblocker and may bind to a SS1 or SS2 a subunit of a sodium channel. Themaximum daily dose of sodium channel blocker may be up to about 10 μg,up to about 50 μg, up to about 100 μg, up to about 144 μg, up to about150 μg, up to about 300 μg, up to about 500 μg, up to about 750 μg, upto about 1000 μg, up to about 1250 μg, up to about 1500 μg, up to about1750 μg, up to about 2000 μg or more. In particular embodiments thesodium channel blocker may be administered in an amount ranging between5 and 4000 μg/day, or in ranges between 10 and 2000 μg/day, 10 and 1000μg a day, 10 and 750 μg a day, 10 and 500 μg a day, 10 and 400 μg a day,10 and 300 μg a day, 10 and 200 μg a day, or 10 and 100 μg/day.

In particular embodiments the daily applied dose may be from about 10 toabout 160 μg, about 10 to about 140 μg, about 10 to about 120 μg, about10 to about 100 μg, about 10 to about 90 μg, about 10 to about 80 μg,about 10 to about 70 μg, about 10 to about 60 μg, about 10 to about 50μg, about 10 to about 40 μg, about 10 to about 30 μg, or 1 to 20 μg. Inother embodiments the daily dosage of the sodium channel blocker May beabout 0.1 to about 40 μg per kilogram of body weight, about 1 to about35 μg per kilogram of body weight, about 5 to about 30 μg per kilogramof body weight, about 10 to about 30 μg per kilogram of body weight,about 15 to about 30 μg per kilogram of body weight, about 10 to about35 μg per kilogram of body weight, or about 20 to about 40 μg perkilogram of body weight. The unit dose may be within a range of about 5μg to about 2000 μg and may be about 5 to about 10 μg, about 1010 about16 μg, about 15 to about 20 μg, about 20 to about 25 μg, about 25 toabout 30 μg, about 30 to about 40 μg, about 40 μg to about 50 μg, about50 μg to about 75 μg, about 15 to about 100 μg, about 100 to about 150μg, about 160 to about 200 μg, about 200 to about 250 μg, about 250 toabout 500 μg, about 500 to about 1000 μg, about 1000 to about 1500 μg orabout 1500 to about 2000 μg or more than 2000 μg.

In some embodiments the dose administered is between 10 and 4000 μg/dayof tetrodotoxin, its derivatives or its analogues, especially the doseof tetrodotoxin administered is normally between 10 and 4000 μg/dayor—given the likely twice per day treatment—between 5 to 2000 μg eachgiven dose, sometimes preferably between 250 and 1000 μg each givendose, sometimes preferably between 25 and 50 μg each given dosedepending on the route of administration.

In some embodiments the effectiveness of a course of treatment of one,two, three, four, five or more doses or one, two or three days may lastfor up to about five, ten, fifteen, twenty, twenty five or thirty. Insome embodiments dosing is only performed once every day or once everytwo, three, four, five, six, seven, eight, nine, ten, eleven, twelve,thirteen, fourteen, sixteen, eighteen, twenty, twenty four, thirty ormore days.

According to the present disclosure, the dosage of said sodium channelblocker such as TTX or SIX, their analogues/derivatives, depends on avariety of factors, including the nature and severity of the diseases;the sex, age, weight and individual reaction of the subject, theparticular compound employed, the route and frequency of administration,etc. Said sodium channel blockers such as TTX or STX, theiranalogues/derivatives or the pharmaceutical compositions comprising themmay be administered in single or divided dosage form, e.g. one to fourdoses per day. Those skilled in the art will readily understand andimplement the changes to the treatment methods exemplified herein thatare necessary or desirable to reflect varied therapeutic requirements.

A substance named as an “active ingredient” with have a purity of atleast 97%. For example, a formulation said to have “500 μg of TTX as theactive ingredient” may 11) contain as much as 15 μg ofanhydrotetrodotoxin as an impurity. On the other hand, a formulationsaid to have “500 μg of TTX and 500 μg of anhydrotetrodotoxin as activeingredients” will contain at least 485 μg of TTX and 485 μg ofanhydrotetrodotoxin, but may contain as much as 30 μg of othersubstances as impurities, of the active ingredients. Of course,substances named as other components of a formulation are not includedwhen the purity of the active ingredient is considered.

In a highly preferred embodiment of the use according to the inventionthe neuropathic pain is peripheral neuropathic pain or peripheralneurogenic pain.

According to the IASP “peripheral neuropathic pain” Is defined as “apain initiated or caused by a primary lesion or dysfunction in theperipheral nervous systems” and “peripheral neurogenic pain” is definedas “a pain initiated or caused by a primary lesion, dysfunction ortransitory perturbation in the peripheral nervous system” (IASP,Classification of chronic pain, 2^(nd) Edition, IASP Press (2002), 213).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is allodynia.

According to the IASP “allodynia” is defined as “a pain due to astimulus which does not normally provoke pain” (IASP, Classification ofchronic pain, 2^(nd) Edition, IASP Press (2002), 210).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is causalgia.

According to the IASP “causalgia” is defined as “a syndrome of sustainedburning pain, allodynia end hyperpathia after a traumatic nerve lesion,often combined with vasomotor and sudomotor dysfunction and latertrophic changes” (IASP, Classification of chronic pain, 2^(nd) Edition,IASP Press (2002), 210).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is hyperalgesia.

According to the IASP “hyperalgesia” is defined as “an increasedresponse to a stimulus which is normally painful (IASP, Classificationof chronic pain, 2^(nd) Edition, IASP Press (2002), 211).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is hyperesthesia.

According to the IMP “hyperesthesia” is defined as “increasedsensitivity to stimulation, excluding the senses” (IASP, Classificationof chronic pain, 2^(nd) Edition, IASP Press (2002), 211).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is hyperpathia.

According to the IASP “hyperpathia” is defined as “a painful syndromecharacterized by an abnormally painful reaction to a stimulus,especially a repetitive stimulus, as well as an increased threshold”(IASP, Classification of chronic pain, 2^(nd) Edition, IASP Press(2002), 212).

The IASP draws the following difference between “allodynia”,“hyperalgesia” end “hyperpathia” (IASP. Classification of chronic pain,2^(nd) Edition, IASP Press (2002), 212);

Allodynia Lowered threshold Stimulus and response mode differHyperalgesia Increased response Stimulus and response rate are the sameHyperpathia Raised threshold; Stimulus and response rate may beIncreased response the same or different

In another preferred embodiment of the use according to the inventionthe neuropathic pain is neuralgia.

According to the IASP “neuralgia” is defined as “Pain in thedistribution of a nerve or nerves” (IASP, Classification of chronicpain, 2^(nd) Edition, IASP Press (2002), 212).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is neuritis.

According to the IASP “neuritis” is defined as “Inflammation of a nerveor nerves” (IASP, Classification of chronic pain, 2^(nd) Edition, (IASPPress (2002), 212).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is neuropathy/neuritis.

According to the IASP “neuritis” is defined as “a disturbance offunction or pathological change in a nerve: in one nerve mononeuropathy,in several nerves mononeuropathy multiplex, if diffuse and bilateral,polyneuropathy” (IASP, Classification of chronic pain, 2^(nd) Edition,IASP Press (2002), 212).

In another preferred embodiment of the use according to the inventionthe neuropathic pain is orofacial pain.

Another aspect of the present invention relates to the use of sodiumchannel blockers such as TTX or STX, its analogues/derivatives,optionally in the form of its racemate, pure stereoisomers, especiallyenantiomers or diastereoisomers or in the form of mixtures ofstereoisomers, especially enantiomers or diastereomers, in any suitablemixing ratio; in neutral form, in the form of an acid or base or in formof a salt, especially a physiologically acceptable salt, or in form of asolvate, especially a hydrate for the production of a medicament for thetreatment of allodynia developing as a consequence of Chemotherapy.

Another aspect of the present invention relates to the use of sodiumchannel blockers such as TTX or STX, its analogues/derivatives,optionally in the form of its racemate, pure stereoisomers, especiallyenantiomers or diastereoisomers or in the form of mixtures ofstereoisomers, especially enantiomers or diastereomers, in any suitablemixing ratio; in neutral form, in the form of an acid or base or in formof a salt, especially a physiologically acceptable salt, or in form of asolvate, especially a hydrate for the production of a medicament for thetreatment of hyperalgesia developing as a consequence of chemotherapy.

In a highly preferred embodiment of the invention the use according tothe invention tetrodotoxin, Its derivative and/or one of its analoguesis used in an amount between 10 μg/day and 4 mg/day.

In a highly preferred embodiment of the invention the use according tothe invention the used tetrodotoxin, its derivative or its analogue isisolated from a biological source, preferably from fish, especiallypuffer fish.

In a highly preferred embodiment of the invention the use according tothe invention the used tetrodotoxin, its derivative or its analogue issynthesized/synthetic.

In a highly preferred embodiment of the invention at least onechemotherapeutic agent used in the chemotherapy is selected from aplatin-derivative, a vinca alkaloid or a taxane.

In a highly profaned embodiment of the invention at least onechemotherapeutic agent used in the chemotherapy is selected from thegroup consisting of cisplatin, carboplatin and oxaliplatin; vincristine,vinblastine, vinorelbine and vindesine; paclitaxel and docetaxel.

Preferably at least one chemotherapeutic agent used in the chemotherapyis cisplatin.

Preferably at least one chemotherapeutic agent used in the chemotherapyis carboplatin.

Preferably at least one chemotherapeutic agent used in the chemotherapyis oxaliplatin.

Preferably at least one chemotherapeutic agent used in the chemotherapyis vincristine.

Preferably al least one chemotherapeutic agent used in the chemotherapyis vinblastine.

Preferably at least one chemotherapeutic agent used in the chemotherapyis vinorelbine.

Preferably at feast one chemotherapeutic agent used in the chemotherapyis vindesine.

Preferably at least one chemotherapeutic agent used in the chemotherapyis paclitaxel.

Preferably at least one chemotherapeutic agent used in the chemotherapyis docetaxel.

Included in this invention are especially also methods of treatment of apatient or a mammal, including men, suffering from neuropathic paindeveloping as a consequence of Chemotherapy using a sodium channelblocker such as tetrodotoxin or saxitoxin and/or one of its analogues orderivatives optionally in the form of its racemate, pure stereoisomers,especially enantiomers or diastereomers or in the form of mixtures ofstereoisomers, especially enantiomers or diastereomers, in any suitableratio; in neutral form, in the form of an acid or base or in form of asalt, especially a physiologically acceptable salt, or in form of asolvate, especially a hydrate. It is also preferred if the method oftreatment is restricted to tetrodotoxin, and/or one of its analogues orderivatives, especially if it is restricted to tetrodotoxin, optionallyin the form of its racemate, pure stereoisomers, especially enantiomersor diastereomers or in the form of mixtures of stereoisomers, especiallyenantiomers or diastereomers, in any suitable ratio; in neutral form. Inthe form of an acid or base or in form of a salt, especially aphysiologically acceptable salt, or in form of a solvate, especially ahydrate. It is also preferred if the method of treatment is restrictedto tetrodotoxin, in neutral form or as a salt, especially aphysiologically acceptable salt, whereas preferably tetrodotoxin, itsderivative end/or one of its analogues is used in an amount between 10μg/day and 4 mg/day, is isolated from a biological source, preferablyfrom fish, especially puffer fish, or is synthesized. It is alsopreferred if the method of treatment is restricted to embodiments inwhich at least one chemotherapeutic agent used in the chemotherapy isselected from a platin-derivative, a vinca alkaloid or a taxane;especially 11 at least one chemotherapeutic agent used in thechemotherapy is selected from the group consisting of cisplatin,carboplatin and oxaliplatin; vincristine, vinblastine, vinorelbine andvindesine; paclitaxel and docetaxel

Especially the above method of treatment includes also a co-treatmentduring chemotherapy, in which the chemotherapeutic drug/drugs areadministered together with the sodium channel blocker such astetrodotoxin or saxitoxin and/or one of its analogues or derivatives,especially TTX or in combination with sodium channel blocker such astetrodotoxin or saxitoxin and/or one of its analogues or derivatives,especially with TTX. This co-treatment could possible happen during thewhole chemotherapy, during parts of the chemotherapy, in the beginningof the chemotherapy, in the middle of the chemotherapy or at the end ofthe chemotherapy.

Another alternative embodiment of the present invention refers to a kitcomprising TTX and/or one of its analogues or derivatives, optionally inthe form of its racemate, pure stereoisomers, especially enantiomers ordiastereomers or in the form of mixtures of stereoisomers, especiallyenantiomers or diastereomers; preferably in any suitable ratio; inneutral form, in the form of an acid or base or in form of a salt,especially a physiologically acceptable salt, or in form of a solvate,especially a hydrate.

Another aspect of the invention is an active substance combinationcomprising

-   -   (A) at least one sodium channel blocker and/or its derivatives,        optionally in the form of its racemate, pure stereoisomers,        especially enantiomers or diastereomers or in the form of        mixtures of stereoisomers, especially enantiomers or        diastereomers, in any suitable mixing ratio; In neutral form, in        the form of en acid or base or In form of a salt, especially a        physiologically acceptable salt, or in form of a solvate,        especially a hydrate;        -   and    -   (B) at least one chemotherapeutic drug.

Another alternative embodiment of this invention is an active substancecombination, wherein the sodium channel blocker (A) is selected fromsaxitoxin, its analogues and/or its derivatives; and/or tetrodotoxin,its analogues and/or its derivatives, optionally in the form of itsrampage, pure stereoisomers, especially enantiomers or diastereomers orIn the form of mixtures of stereoisomers, especially enantiomers ordiastereomers. In any suitable mixing ratio; in neutral form, in theform of an add or base or in form of a salt, especially aphysiologically acceptable salt, or in form of a solvate, especially ahydrate;

-   -   especially the sodium channel blocker (A) is selected from        tetrodotoxin, its analogues and/or its derivatives, optionally        in the form of its racemate, pure stereoisomers, especially        enantiomers or diastereomers or in the form of mixtures of        stereoisomers, especially enantiomers or diastereomers, in any        suitable mixing ratio; in neutral form, in the form of an acid        or base or in form of a salt, especially a physiologically        acceptable salt, or in form of a solvate, especially a hydrate;    -   more especially the sodium channel blocker (A) is selected from        tetrodotoxin, optionally in the form of its racemate, pure        stereoisomers, especially enantiomers or diastereomers or in the        form of mixtures of stereoisomers, especially enantiomers or        diastereomers. In any suitable mixing ratio; in neutral form, in        the form of an acid or base or in form of a salt, especially a        physiologically acceptable salt, or in form of a solvate,        especially a hydrate.

Another alternative embodiment of this invention is an active substancecombination, wherein the chemotherapeutic drug (B) is selected from isselected from a platin-derivative, a vista alkaloid or a taxane,

-   -   especially the chemotherapeutic drug (B) is selected from is        selected from cisplatin, carboplatin and oxaliplatin;        vincristine, vinblastine, vinorelbine and vindesine; paclitaxel        and docetaxel.

Another alternative embodiment of this invention is an active substancecombination, wherein the sodium channel blocker (A) is selected fromsaxitoxin. Its analogues and/or its derivatives; and/or tetrodotoxin,its analogues and/or its derivatives, optionally in the form of itsracemate, pure stereoisomers, especially enantiomers or diastereomers orin the form of mixtures of stereoisomers, especially enantiomers ordiastereomers. In any suitable mixing ratio; in neutral form. In theform of an acid or base or in form of a salt, especially aphysiologically acceptable salt, or in form of a solvate, especially ahydrate;

-   -   especially the sodium channel blocker (A) is selected from        tetrodotoxin, its analogues and/or its derivatives, optionally        in the form of its racemate, pure stereoisomers, especially        enantiomers or diastereomers or in the form of mixtures of        stereoisomers, especially enantiomers or diastereomers, in any        suitable mixing ratio; in neutral form, in the form of an acid        or base or in form of a salt, especially a physiologically        acceptable salt, or in form of a solvate, especially a hydrate;    -   more especially the sodium channel blocker (A) is selected from        tetrodotoxin, optionally in the form of its racemate, pure        stereoisomers, especially enantiomers or diastereomers or in the        form of mixtures of stereoisomers, especially enantiomers or        diastereomers, in any suitable mixing ratio; in neutral form, in        the form of en acid or base or In form of a salt, especially a        physiologically acceptable salt, or In form of a solvate,        especially a hydrate;    -   AND    -   the chemotherapeutic drug (B) Is selected from a        platin-derivative, a vine alkaloid or a taxane,    -   especially the chemotherapeutic drug (B) is selected from is        selected from cisplatin, carboplatin and oxaliplatin;        vincristine, vinblastine, vinorelbine and vindesine; paclitaxel        and docetaxel.

Another highly preferred alternative embodiment of this invention is anactive substance combination, wherein the sodium channel blocker (A) istetrodotoxin; and the chemotherapeutic drug (B) is selected fromcisplatin, carboplatin and oxaliplatin; vincristine, vinblastine,vinorelbine and vindesine; paclitaxel and docetaxel.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and cisplatin.

Another highly preferred alternative embodiment of this invention is enactive substance combination, of tetrodotoxin and carboplatin.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and oxaliplatin.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and vincristine.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and vinblastine.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and vinorelbine.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and vindesine.

Another highly preferred alternative embodiment of this invention is enactive substance combination, of tetrodotoxin and paclitaxel.

Another highly preferred alternative embodiment of this invention is anactive substance combination, of tetrodotoxin and docetaxel.

Another highly preferred aspect of the invention is the use of a sodiumchannel blocker and/or its derivatives, such as TTX or STX, Itsanalogues/derivatives, optionally in the form of its racemate, purestereoisomers, especially enantiomers or diastereomers or In the form ofmixtures of stereoisomers, especially enantiomers or diastereomers, inany suitable mixing ratio; in neutral term, in the form of an acid orbase or in form of a salt, especially a physiologically acceptable salt,or in form of a solvate, especially a hydrate for the production of amedicament for the treatment of orofacial pain, preferably in the formof neuropathic pain, hyperalgesia or allodynia, more preferably in theform of neuropathic pain, hyperalgesia or allodynia, developing as aconsequence of chemotherapy.

The orofacial region, the face and mouth, represent sites of some of themost common pains in the body. Epidemiological studies have revealed thehigh prevalence of several facial pain conditions such astemporomandibular disorders (TMD), burning mouth syndrome, andtoothaches, (Dworkin, 2001; Feinman end Newton-John, 2004; LeResche,2001; Lipton et at, 2001). Many of the difficulties experienced byclinicians with the management of acute and chronic orofacial painconditions stem from a lack of recognition and understanding of theircomplex factors and interactions, from uncertainties of the aetiology orpathogenesis of many of the conditions, as well as from the lack ofinformation of the comparative effectiveness of the analgesic drugs onorofacial pain.

The examples and figures in the following section describingpharmacological trials are merely illustrative and the invention cannotbe considered in any way as being restricted to these applications.

EXAMPLES Pharmacological Experiments Experimental Group 1

Recently, models of paclitaxel-induced painful neuropathy have beendeveloped in mice and rats. These models demonstrated that repeatedadministration of paclitaxel produced mechanical hyperalgesia andallodynia Outlier et al., 2000; Polomano et al., 2001; Dina et al., 2001y 2004; Smith et al., 2004; Flatters y Bennett, 2004), cold allodynia(Polomano et al., 2001; Smith at al., 2004; Flatters y Bennett, 2004)and in some studies a thermal (warm) hyperalgesia (Polomano et al.,2001; Dina et. al., 2001; Flatters y Bennett, 2004); however, otherstudies did not find this thermal hyperalgesia (Authier et al, 2000;Smith et al., 2004). Therefore, paclitaxel-induced painful neuropathy inrodents represents an interesting model to test the effects of drugs inneuropathic pain.

FIGURES

FIG. 1: Time-course of paclitaxel induced thermal hyperalgesia,cold-allodynia and mechanical allodynia in mice. Animals were treatedonce defy from days 1 to 5 with paclitaxel (2 mg/kg) or its vehicle viai.p. The latency to hind paw withdrawal in the plantar teat (A), theduration of hind paw licking/biting in the acetone test (B) and thethreshold force for hind paw withdrawal in the Von Fray test (C) wasrecorded 3 days before (PRE) end at several days after the firstinjection of paclitaxel or its vehicle. Each animal was tested only inone nociceptive model. Each point and vertical line represents themean±S.E.M. of the values obtained in at least 12 mice. Statisticallysignificant differences between the values or paclitaxel- andvehicle-treated groups: *p<0.05; **p<0.01; and between the values onpre-treatment day and the days after treatment: # p<0.05; ## p<0.01(two-way repeated measures ANOVA followed by Newman-Keuls test).

FIG. 2: Time-course of the effect of co-administration of paclitaxel+TTX(3 or 6 μg/kg) or paclitaxel+saline on latency to hind paw withdrawal inthe plantar test (A), duration of hind paw licking/biting in the acetonetest (B) and threshold force for hind paw withdrawal in the Von Freytest (C). Mice were treated once dolly from days 1 to 5 with an s.c.Injection of TTX (3 or 6 μg/kg) or saline 30 minutes before each i.p.injection of paclitaxel (2 mg/kg). The response evaluated was recordedin each animal 3 days before (PRE) and at several days attar the firstinjection of paclitaxel+TTX or paclitaxel+saline. Each animal was testedonly in one nociceptive model. Each point and vertical line representsthe mean±S.E.M. of the values obtained in at least 16 animals. Nostatistically significant differences between the values of both groupsof treatment were found in the plantar test, but only a slight tendencycan be seen. Statistically significant differences in comparison topaclitaxel+saline: *p<0.05, **p<0.01; and between the values onpre-treatment day and the days after treatment: # p<0.05, ## p<0.01(two-way repeated measures ANOVA followed by Newman-Keuis test).

FIG. 3: Time-course of the effect on the latency to hind paw withdrawal(plantar test) of a single s.c. injection of tetrodotoxin (TTX; 3 or 6μg/kg) or saline in mice pre-treated with (A) paclitaxel or (B)paclitaxel-vehicle. Animals were treated once daily from days 1 to 5with paclitaxel or its vehicle via i.p. and the day 7 received a singles.c. injection of TTX or saline. The latency to hind paw withdrawal wasrecorded in each animal 3 days before (PRE) and 7 days after the firstinjection of paclitaxel or its vehicle. This day, paw withdrawal latencywas recorded immediately before (time 0) and at several times (30, 60,90, 120 and 180 min) after the injection of TTX or saline. Each animalreceived either saline or one dose of TTX. Each point and vertical linerepresents the mean±S.E.M. of the values obtained in at least 12animals. (A) Statistically significant differences among the values ofTTX- and saline-treated groups at the same time after treatment *p<0.06;**p<0.01; and between the values on pre-treatment day and the days aftertreatment: # p<0.05; ## p<0.01 (two-way repeated measures ANOVA followedby Newman-Keels test). (B) No statistically significant differencesamong the values of the three groups ware observed at any observationtime, nor in comparison with their own pre-treatment day values (two-wayrepeated measures ANOVA).

FIG. 4: Time-course of the effect on the duration of hind pawlicking/biting (acetone teal) of a single s.c. injection of tetrodotoxin(TTX; 3 or 6 μg/kg) or saline in mice pre-treated with (A) paclitaxel or(B) paclitaxel-vehicle. Animals were treated once deity from days 1 to 5with paclitaxel or its vehicle via i.p. and the day 14 received a singles.c. injection of TTX or saline. The duration of hind paw licking/bitingwas recorded in each animal 3 days before (PRE) end 14 days after thefirst injection of paclitaxel or its vehicle. This day, duration of hindpaw licking/biting was recorded immediately before (time 0) and atseveral times (60, 120 and 180 min) after the injection of TTX orsaline. Each animal received either saline or one dose of TTX. Eachpoint and vertical line represents the mean±S.E.M. of the valuesobtained in at least 12 animals. (A) Statistically significantdifferences among the values of TTX- and saline-treated groups at thesame time after treatment **p<0.01; and between the values onpre-treatment day and the days after treatment: ## p<0.01 (two-wayrepeated measures ANOVA followed by Newman-Keuis test). (B) Nostatistically significant differences between the values of the twogroups were observed at any observation time, nor in comparison withtheir own pre-treatment day values (two-way repeated measures ANOVA).

FIG. 5: Time-course of the effect on the threshold force for hind pawwithdrawal (Von Frey test) of a single s.c. injection of tetrodotoxin(TTX; 3 or 6 μg/kg) or saline in mice pre-treated with (A) paclitaxel or(B) paclitaxel-vehicle. Animate were treated once daily from days 1 to 5with paclitaxel or its vehicle via i.p. and the day 10 received a singles.c. injection of TTX or saline. The threshold force for hind pawwithdrawal was recorded in each animal 3 days before (PRE) and 10 daysafter the first injection of paclitaxel or its vehicle. This day, pawwithdrawal latency was recorded immediately before (time 0) and atseveral times (30, 60, 90, 120 and 180 min) after the injection of TTXor saline. Each animal received either saline or one dose of TTX. Eachpoint and vertical line represents the mean±S.E.M. of the valuesobtained in at least 12 animals. (A) Statistically significantdifferences among the values of TTX- and saline-treated groups at thesame time after treatment: **p<0.01: and between the values onpre-treatment day and the days after treatment: ## p<0.01 (two-wayrepeated measures ANOVA followed by Newman-Keuls test). (B) Nostatistically significant differences among the values of the threegroups were observed at any observation time, nor in comparison withtheir own pre-treatment day values (two-way repeated measures ANOVA).

Methods:

In general:

Experiments were performed in CD-1 mice (Charles River, S.A.) withn=10/experimental group. Paclitaxel-induced painful peripheralneuropathy was produced by i.p. administration of paclitaxel once dallyduring two weeks as previously described (Dina et al., 2001), controlanimals received the same volume of solvent (a mixture of ethanol andcremophor EL)

-   -   Mechanical hyperalgesia and allodynia was evaluated with Von        Frey filaments and a Randall-Sellito paw-pressure analgesymeter        (Dina et al, 2001; Flatters and Bennet, 2004), cold allodynia        was evaluated using the acetone drop method (Polomano et al.,        2001; Smith et al., 2004), whereas thermal hyperalgesia was        measured with the Hargreaves method (Dina et al., 2001; Polomano        et al., 2001).

TTX exerted clear analgesic effects in this model of neuropathic pain.

TTX was injected s.c. immediately before each pacilitaxel injection totest whether TTX effect the development of the painful peripheralneuropathy or In the third week (when paclitaxel injection have endedand the neuropathy is fully developed) to test whether fix interfereswith the expression of the different signs of paclitaxel-inducedneuropathic pain.

Specific Description:

Animals.

Female CD-1 mice weighing 26-30 g were used. The animals were housed incolony cages with free access to food and water prior to theexperiments. They were maintained in temperature- and light-controlledrooms (22±1° C. lights on at 08.00 h and off at 20.00 h, air replacementevery 20 min). Testing took place during the light phase (from 9.00 h to15.00 h).

Paclitaxel was dissolved in a solution made up of 50% Cremophor EL and50% absolute ethanol to obtain a concentration of 8 mg/ml. Thispaclitaxel solution was conserved at −20° C. during a maximum of 14 daysand was diluted in normal saline (NaCl 0.9%), just beforeadministration, to a final concentration of 2 mg/10 ml. The vehicle ofpaclitaxel was diluted at the time of injection with saline (NaCl 0.9%)in the same proportion as the paclitaxel solution.

Paclitaxel (2 mg/kg) was administered intraperitoneously (i.p.), in avolume of 10 ml/kg, once per day for live consecutive days. Therefore,the cumulative dose was 10 mg/kg per mouse. In the control group thevehicle of paclitaxel was administered following the same schedule.

TTX base solution (concentration of 15 μg/ml), was diluted in normalsaline just before administration to final concentrations of 3 and 6μg/5 ml. The injection of TTX (3 or 6 μg/kg) or its solvent (normalsaline) was administered subcutaneously (s.c.) in the interscapulararea, using an injection volume of 5 ml/kg.

The effects of s.c. TTX on paclitaxel-induced neuropathic pain wereexamined in two different ways. To evaluate the effect of TTX on thedevelopment of paclitaxel-Induced pain, the animals received firstly as.c. injection of TTX 30 rein before each i.p. injection of paclitaxelfor five consecutive days. Posteriorly the response of the animals tothe different nociceptive stimuli was tested during 2-4 weeks, dependingon the test (see below), without any additional treatment. Each animalwee tested only in one nociceptive model. To test the effect of TTX onthe expression of paclitaxel-Induced pain a single TTX injection wasperformed the day of maximum expression of thermal hyperalgesia (day 7from the beginning of paclitaxel administration), mechanical allodynia(day 10) or cold allodynia (day 14) (see results for details). Eachanimal received only one dose of TTX and was tested in only onenociceptive model.

Procedure for Assessment of Heat Hyperalgesia.

Thermal hyperalgesia was assessed by the following method; Mice werehabituated in individual Plexiglass chambers (7×7×22 cm), pieced atop aglass floor, during two hours, During this time, mice initiallyexhibited exploratory behaviour but subsequently stopped exploring andstood quietly with occasional bouts of grooming. After habituation, abeam of radiant heat was focused to the plantar surface of the hindpaws, using a plantar test apparatus (Ugo Basile, Cornerio, Italy),until the mouse made a withdrawal response. The nocifensive withdrawalreflex interrupts the light reflected from the paw onto a photocell andautomatically turns off the tight and a timer. Therefore, the latency towithdrawal value (that indirectly indicated the heal-pain threshold) wasautomatically recorded.

The intensity of the light was adjusted at the start of the experimentssuch that average baseline latencies were about 8 s. This intensity wasnever changed. Each mouse was tested three times alternately on eachhind paw and the latencies for both paws were averaged together in eachmeasurement time. At least, one minute was allowed between consecutivesame paw attempts. A cut-off latency time of 16 seconds was imposed ineach measurement in order to avoid lesions to the skin end unnecessarysuffering to the animals.

To elucidate the time-course of paclitaxel-induced heat hyperalgesia incontrol mice, pretreatment baseline latencies were obtained three daysbefore drug treatment. Then, animals were treated with paclitaxel or itsvehicle once daily during 6 days, Postreatment latencies were assessedon days 7, 10, 14 and 17 after the fleet injection of paclitaxel. Whenthe effect of TTX on the development of paclitaxel-induced heathyperalgesia was tested, the procedure was the same except that TTX orits solvent was s.c. injected 30 min before each daily dose ofpaclitaxel or its vehicle (i.p.) during the 6 days of treatment. Theeffect of TTX on the expression of paclitaxel-induced heat-hyperalgesiawas tested on day 7 after the first injection of paclitaxel, since themaximum heat hyperalgesia was observed that day. Therefore, on day 7,after the habituation period to the apparatus, baseline latencies worerecorded and immediately later TTX or its solvent was injected s.c., pawwithdrawal latencies were assessed again 30, 80, 90, 120 and 180 minutesafter the injection. Around 9% of the animals treated with paclitaxeldid not developed thermal hyperalgesia the day 7 afterpaclitaxel-treatment. These animals were not used to evaluated theeffect of TTX on the expression of paclitaxel-Induced thermalhyperalgesia.

Procedure for Assessment of Cold Allodynia.

Cold allodynia was tested as previously described by Smith et al., 2004,by gently touching the plantar skin of the hind pews with an acetonebubble formed with a syringe connected to a thin polyethylene tube. Themice were housed end habituated for 30 min in transparent plastic boxes(7×7×13 cm) with a floor made of wire mesh. After the adaptation period,acetone was applied alternately three times to each paw at intervals of30 s, and the duration and frequency of licking or biting ware recorded.A small mirror was placed behind the chambers to allow clear observationof the paws. The time spent licking or biting the paw was recorded by astopwatch and represented as the cumulative time of licking/biting inthe six measurements. Since in the experiments licking persisting morethan 10 s was very unusual, a cut-off time of 10 s was used to eachtrial. The frequency of licking/biting was expressed as a percentage,and calculated with the following formula: (number of trials accompaniedby licking or biting/total number of trials)×100.

To elucidate the time-course of paclitaxel-induced cold allodynia incontrol mice, the animals were tested previously to paclitaxeladministration (pretreatment value) and on different days (days 7, 10,14, 17, 21 and 24) alter the first paclitaxel or vehicle injection. Thesame procedure was followed to test the effect of TTX on the developmentof cold allodynia, but in this case, TTX or its solvent was s.c.injected 30 min before each of the 5 paclitaxel i.p. injections. Becausethe maximum allodynic effect induced by paclitaxel was observed on days10-14 after its first injection, the effects of TTX on the expression ofcold allodynia was assessed on day 14. This day, once baseline responseto acetone was recorded the animals received an s.c. injection of TTX orits solvent, and the response to acetone was recorded again at 60, 120and 180 min after the injection. Around 33% of the control animalstreated with paclitaxel, did not show cold allodynia; therefore, it wasdifferentiated between ‘responders’ and ‘non-responders’ mice in thistest. The ‘non-responders’ mice were easily identified because theyspent less than 2 s licking/biting the paw stimulated with acetone ondays 7 end 10 after paclitaxel administration. The ‘non-responder’animate were not used to test the effect of TTX on the expression ofcold allodynia since they do not express enough cold allodynia.

Procedure for Assessment of Mechanical Allodynia.

To assess mechanical allodynia, paw withdrawal thresholds were measuredusing a Dynamic Plantar Aesthesiometer (Ugo Basile, Italy), Theelectronic Von Frey device employs a single nonflexible filament whichapplies a progressively increasing force (from 0 to 10 g) against theplantar surface of the hind paw over a 20 a period. The nocifensivewithdrawal reflex automatically turns off the stimulus and themechanical threshold value is showed in a screen. The day of theexperiment mice were placed individually in test compartments (9×9×14cm) with a wire mesh bottom and allowed to acclimatize to them for 2 h.After habituation, each mouse was tooted three times alternately in eachhind paw.

To elucidate the time-course of paclitaxel-induced mechanical allodyniain control mice, the animals were tested previously to paclitaxeladministration (pretreatment value) and on different days (days 7, 10,14 and 17) after the first paclitaxel or vehicle injection. The sameprocedure was followed to test the effect of TTX on the development ofpaclitaxel-induced mechanical allodynia, except that TTX or its solventwas s.c. injected 30 min before each daily dose of paclitaxel or itsvehicle (i.p.) during the 5 days of treatment. The effect of TTX on theexpression of paclitaxel-induced mechanical allodynia was evaluated onday 10, because the maximum change of the mechanical threshold wasobserved on that day. Therefore, the day 10, after the habituationperiod to the apparatus, baseline latencies were recorded, subsequentlyTTX or its solvent was injected s.c. and paw withdrawal latencies wereassessed again 30, 60, 90, 120 and 180 minutes after the injection. Mostanimals (96%) treated with pacilitaxel showed a reduction of themechanical threshold; those animals that did not show mechanicalallodynia wore not used to test the effect of TTX on the expression ofpaclitaxel-induced mechanical allodynia.

Results

Time-Course of Paclitaxel-Induced Thermal Hyperalgesia, Cold- andMechanical-Allodynia in Control Mice.

The values obtained on the pre-treatment day in paclitaxel- andvehicle-treated animals were not significantly different in plantar test(FIG. 1A), acetone test (FIG. 1B) and Von Frey test (FIG. 1C).Administration during 5 days of pacilitaxel-vehicle did notsignificantly modify the response of the animate in any test at anypost-treatment day in comparison to the pre-treatment value (FIGS.1A-C). On the other hand, 5 days of treatment with paclitaxel (2 mg/kg,i.p.) significantly reduced the paw withdrawal latency values in theplantar test all the post-treatment days, in comparison to thepre-treatment day value (FIG. 1A). Paclitaxel-induced thermalhyperalgesia was maximal 7 days after the first injection of theantineoplastic (FIG. 1A); therefore, the effect of TTX on the expressionof thermal hyperalgesia was evaluated on day 7.

In the acetone test, administration of paclitaxel (2 mg/kg, i.p.) oncedaily during 5 days permit to distinguish two groups of animalsdepending on their response. Most animals (67%) treated with paclitaxelsignificantly (p<0.01) increased the time spent licking/biting the pawstimulated (FIG. 1B) and the frequency of paw licking/biting all thepost-treatment days, in comparison to the pre-treatment day value. Theseanimals constitute the paclitaxel-responder animals. On the other hand,a 33% of paclitaxel-treated animals did not show cold allodynia, andtheir response to acetone was indistinguishable from that of animalstreated with paclitaxel-vehicle in both duration (FIG. 1B) and frequencyof licking/biting. When the values of these two variables among thedifferent groups on the same day of evaluation were compared,statistically significant differences between paclitaxel-responder andthe other two groups (paclitaxel-non-responder or paclitaxel-vehicle)each day of evaluation after treatment (FIG. 1B) was observed,Paclitaxel-induced cold allodynia was maximal 10-14 days after the firstinjection of the antineoplastic for both variables recorded (FIG. 1B);therefore, the effect of TTX on the expression of cold allodynia wasevaluated on day 14.

Administration of paclitaxel (2 mg/kg, i.p., during 5 days) inducedmechanical allodynia in mice, since it significantly reduced thethreshold force for pew withdrawal in the Von Frey test on day 10, incomparison both with the pre-treatment day value and with the valueobtained the same day in the paclitaxel-vehicle treated animals (FIG.1C). Therefore, the effect of TTX on the expression of mechanicalallodynia was tested on day 10.

Effect of tetrodotoxin (TTX) on the development of paclitaxel-inducedthermal hyperalgesia, cold- and mechanical-allodynia. The pro-treatmentvalues were similar in the two experimental groups (paclitaxel+salineand paclitaxel+TTX) in all test performed (plantar, acetone end Von Freytests) (FIGS. 2A, 2B and 2C).

In the planter test, the paw withdrawal latency values weresignificantly tower than the pre-treatment values in both experimentalgroups at all times evaluated from 7 to 17 days after the firstinjection of paclitaxel (FIG. 2A). However, there were no significantdifferences between the values of paw withdrawal latency (throughout the17 days of measurements) after the co-administration of paclitaxel TTX 6μg/kg in comparison to that obtained after paclitaxel saline (FIG. 2A)and only a slight tendency can be seen. Therefore, co-administration ofpaclitaxel end TTX seem to have only a very limited effect on thedevelopment of thermal hyperalgesia induced by paclitaxel.

The group of animals in which paclitaxel (i.p.) and saline (s.c.) wereco-administered during days 1 to 5 showed a significant increase onduration of paw licking/biting (FIG. 2B) and en increase in thefrequency of paw licking/biting, which became maximum on days 10-14after the first injection, like in the experiments were only paclitaxelwas injected (FIG. 16). On the other hand, in the animals which receivean s.c. injection of TTX (6 μg/kg) 30 min before each dose of i.p.paclitaxel during days 1 to 5, the duration and the frequency of pawlicking/biting (throughout the 24 days after co-administration) werenon-significantly different from that obtained on pre-treatment day(FIG. 2B). Moreover, statistically significant differences between thevalues obtained in both groups (paclitaxel saline end paclitaxel TTX 6μg/kg) were observed on days 10 and 14 when duration of ticking/bitingwas analysed (FIG. 2B), and on days 7, 10 and 14 when frequency oflicking/biting was considered. Therefore, co-administration ofpaclitaxel i.p. and TTX 6 μg/kg s.c. inhibited the development of coldallodynia induced by paclitaxel. The effect of co-administration ofpaclitaxel with a lower dose of TTX (3 μg/kg) was also evaluated, butthis dose of TTX did not significantly affect the development ofpaclitaxel-induced cold allodynia in the two variables evaluated.

The paw withdrawal threshold force values (Von Frey test) inpaclitaxel+saline treated animals were significantly lower than thepre-treatment values on days 10 and 14 after the first injection ofpaclitaxel (FIG. 2C). However, there were no significant differencesbetween the pretreatment and post-treatment values at any day in theanimals treated with paclitaxel+TTX 3 or 6 μg/kg (FIG. 2C). Moreover,there were statistically significant differences between the values ofpew withdrawal threshold force after the ix-administration of paclitaxelwith TTX 3 or 6 μg/kg in comparison to that obtained after paclitaxelwith saline on days to and 14 (FIG. 2C). Therefore, co-administration ofpaclitaxel and TTX inhibited the development of mechanical allodyniainduced by paclitaxel in mice.

Effect of Tetrodotoxin (TTX) on the Expression of Paclitaxel-InducedThermal Hyperalgesia.

The values of paw withdrawal latency in the plantar test, recorded onday 7, before the administration of TTX or saline (time 0), weresignificantly different from their values on pre-treatment day in allgroups of animals that have been treated with paclitaxel (FIG. 3A, time0 versus PRE); i.e., as expected, paclitaxel induced thermalhyperalgesia 7 days after its first injection. Saline administration attime 0 did not significantly modify paclitaxel-induced thermalhyperalgesia. The saline-treated mice kept all their values of pawwithdrawal latency during the 3 hours after its injectionnon-significantly different from that at time 0; whereas, all thesevalues were significantly different (p<0.01) from the latency valueobtained before paclitaxel administration (PRE value) (FIG. 3A). On theother hand, the s.c. administration of TTX (3 or 6 μg/kg) inhibitedpaclitaxel-induced thermal hyperalgesia in a dose-dependent manner. Thiseffect of TTX was significantly different from that of saline from 30 to120 minutes after injection of TTX 6 μg/kg, and from 60 to 120 minutesin the group of mice treated with TTX 3 μg/kg (FIG. 3A). Therefore,acute administration of TTX inhibited the expression ofpaclitaxel-Induced thermal hyperalgesia.

As expected, 5 days of treatment with paclitaxel-vehicle did notsignificantly change the paw withdrawal latency value on day 7 (FIG. 3B,time 0 versus PRE). In these animals, the s.c. administration of TTX (3or 6 μg/kg) or saline did not significantly effect paw withdrawallatency values induced by a thermal stimulus during the 3 hours ofrecording (FIG. 3B). Hence, TTX administration did not modify theresponse to a painful thermal stimulus in control animals.

Effect of Tetrodotoxin (TTX) on the Expression of Paclitaxel-InducedCold Allodynia.

The duration and the frequency of paw licking/biting on day 14, beforethe treatment with TTX or saline, were significantly different fromtheir values on pre-treatment day in all groups of animals treatedduring 5 days with paclitaxel (FIG. 4A, time 0 versus PRE.); i.e., asexpected, paclitaxel induced a cold allodynia 14 days after its firstinjection. A single s.c., injection of saline on day 14 did notsignificantly modify the expression of paclitaxel-induced coldallodynia. The saline-treated mice kept the values of the two variablesevaluated during the 3 hours after its injection non-significantlydifferent from that at time 0; while, all these values weresignificantly different (p<0.01) from the values obtained beforepaclitaxel administration (PRE value) (FIG. 4A). On the other hand, theacute treatment with TTX (3 or 6 μg/kg; s.c.) inhibited the expressionof paclitaxel-induced cold allodynia. This effect of TTX wassignificantly different from that of saline 1 h after the injection ofTTX 3 or 6 μg/kg when duration of licking/biting was evaluated (FIG.4A), and only in the animals treated with TTX 8 μg/kg when frequency oflicking/biting was evaluated.

As expected, treatment with paclitaxel-vehicle during 6 days did notsignificantly change the duration and the frequency of pawlicking/biting on day 14 (FIG. 4B; time 0 versus PRE,). In these mice,the administration on day 14 of a single s.c. Injection of saline or TTX(6 μg/kg) did not significantly change, in comparison to thepretreatment values, the duration (FIG. 4B) and the frequency of pawlicking/biting values during the 3 h of evaluation. Therefore, theadministration of paclitaxel-vehicle did not induce cold allodynia inthe acetone test on day 14, and a single injection of TTX did not affectthe basal response to acetone in this test.

Effect of Tetrodotoxin (TTX) on than Expression of Paclitaxel-InducedMechanical Allodynia.

On day 10, before the administration of TTX or saline the values ofthreshold force in the Von Fray test were significantly lower than thevalues on pre-treatment day in paclitaxel-treated group (FIG. 5A, time 0versus PRE). i.e., as expected, the antineoplastic induced mechanicalallodynia 10 days aster its first injection. Saline (TTX-solvent)administration at time 0 did not significantly modify paclitaxel-inducedmechanical allodynia. Mice treated with saline kept all their values ofthreshold force during 3 hours after its injection non-significantlydifferent from that obtained at time 0; whereas, all values from 0 to180 minutes were significantly different (p<0.01) in comparison to thatobtained on pre-treatment day (FIG. 5A). On the other hand, the s.c.,administration of TTX (1 end 3 μg/kg) Inhibited mechanical allodyniainduced by paclitaxel. This effect of TTX was statistically significant(p<0.01) from 30 to 90 minutes after TTX administration in both groupsof TTX-treated animals (1 end 3 μg/kg) in comparison to sauna-treatedanimals (FIG. 5A).

As expected, 5 days of treatment with paclitaxel-vehicle did notsignificantly change the value of the threshold force for hind pawwithdrawal on day 10 (FIG. 5B, time 0 versus PRE). The subcutaneousadministration of TTX (3 or 6 μg/kg, s.c.) or saline, did notsignificantly modify the threshold force in those animals (FIG. 5B).Therefore, TTX administration did not alter the response to a mechanicalstimulus in control animals.

Discussion

It was found that acute administration of TTX inhibited the expressionof paclitaxel induced heat-hyperalgesia, mechanical- and cold-allodyniain mice, and that repeated co-administration of TTX and paclitaxelprevented the development of both kinds of allodynia without dearlyaffecting heat-hyperalgesia

REFERENCES

-   Alberts D S, Noel J K, Cisplatin associated neurotoxicity: can it be    prevented? Anticancer Drugs. 1998 June; 6(3):369-83.-   Authier N, Glillel J P, Fialp, J, Eschalier A, Coudore F.    Description of a short-term Taxol-induced nociceptive neuropathy in    rate. Brain Res. 2000 Dec. 29; 887(2):239-49.-   Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Coenblath    D R. Peripheral neuropathy from taxol and cisplatin combination    chemotherapy: clinical and electrophysiological studies. Ann Neurol.    1994 March; 35(3):304-11.-   Dina O A, Chen X, Reichling D. Levine J D. Role of protein kinase    Cepsilon and protein kinase A in a model of paclitaxel-induced    painful peripheral neuropathy in the rat. Neuroscience. 2001;    109(3):507-15.-   Dina O A. Parada C A, Yeh J, Chen X, McCarter G C, Levine J D.    Integrin signaling in inflammatory and neuropathic pain in the rat    Eur J Neurosci. 2004 February; 19(3):634-42.-   Flatters S J, Bennett G J. Ethoeuximide reverses paclitaxel- and    vincristine-induced painful peripheral neuropathy. Pain. 2004 May;    109(1-2):150-61.-   Forsyth P A, Balmacede C, Peterson K, Seidman A D, Brasher P,    DeAngelis L M Prospective study of paclitaxel-Induced peripheral    neuropathy with quantitative sensory testing. J Neurooncol. 1997    October; 35(1):47-53.-   Gordon A N, Stringer C A, Matthews C M, Willis D L, Nemunaitis J.    Phase I dose escalation of paclitaxel in patients with advanced    ovarian cancer receiving cisplatin: rapid development of    neurotoxicity is dose-limiting. J Clin Oncol. 1997 May;    15(5):1966-73.-   Polomano R C, Bennett G J. Chemotherapy-evoked painful peripheral    neuropathy. Pain Med. 2001 March; 2(1);8-14.-   Polomano R C, Mannes A J, Clark U S, Bennett G J. A painful    peripheral neuropathy in the rat produced by the chemotherapeutic    drug, paclitaxel. Pain. 2001 December; 94(3):293-304.-   Postma T J, Vermorken J B, Liefting A J, Pinedo H M, Heimans J J.    Paclitaxel-induced neuropathy. Ann Oncol. 1995 May; 6(5):489-94.-   Questhoff S, Hartung H P. Chemotherapy-induced peripheral    neuropathy, J Neurol. 2002 January; 249(1):9-17.-   Rowinsky E K, Eisenhauer E A, Chaudhry V, Arbuck S G, Donehower R C.    Clinical toxicities encountered with paclitaxel (Taxol). Semin    Oncol. 1993a August; 20(4 Suppl 3):1-15.-   Rowinsky E K, Chaudhry V, Foreshore A A, Sertortus S E, Ettinger D    S, Grochow L B, Lubajko B G, Cornblath D R, Donehower R C. Phase I    and pharmacologic study of paclitaxel and cisplatin with granulocyte    colony-stimulating factor: neuromuscular toxicity is dose-limiting.    J Clin Oncol. 1993b October; 11(10):2010-20.-   Smith S B, Cragor S E, Mogil J S, Paclitaxel-induced neuropathic    hypersensitivity in mice: responses in 10 inbred mouse strains. Life    Sci. 2004 Apr. 9; 14(21):2593-604.-   Wasserhelt C, Frazein A, Draft R, Sorich J, Downey A, Hochster H,    Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J, Phase    II trial of paclitaxel and cisplatin in women with advanced breast    censer: an active regimen with limiting neurotoxicity. J Clin Oncol.    1996 July; 14(7):1993-9, Erratum in: J Clin Oncol 1996 December;    14(12):3175.

Experimental Group 2

Recently, several new animal models have been proposed to study themechanisms underlying the development of these neuropathies, such ascontinuous intravenous injection of vincristine in rata andintraperitoneal (i.p.) administration of paclitaxel (Polomano et al.,2001).

Analgesic effectiveness of TTX was tested on a model of neuropathic paininduced by paclitaxel.

FIGURES

FIG. 6. Development of allodynia end hyperalgesia after paclitaxel andpaclitaxel vehicle control treatment in orofacial (A) and paw region (B,C). Data is expressed as the percentage (%) of the mean pre-paclitaxelcontrol response±SEM recorded from B (before paclitaxel treatment) today 29, Tn=day where paclitaxel was injected. *Statistical difference vsvehicle group (*p<0.05, ***p<0.001, one way ANOVA plus post hocBonferroni test) n=9.

FIG. 7. Effect of a single injection of TTX on orofacial allodynia (A)paw allodynia (B) and paw hyperalgesia (C). Bars shows the meanthreshold (g)±SEM recorded on day 0 (before paclitaxel treatment), onday 21 and on day 22 after paclitaxel injection. +Statistical differencevs day 0, *Statistical difference vs day 21, (one way ANOVA plus posthoc Bonferroni test). *p<0.05, **p<0.01, ***p<0.001.

FIG. 8. Effect of TTX on time course of paclitaxel-Induced allodynia incontrol animals. Data is expressed as the percentage of the meanpre-paclitaxel control threshold±SEM recorded from day 0 (beforepaclitaxel treatment) to day 29 in control rats and in rats treated withchronic TTX, Tn=day where paclitaxel was injected. *Statisticaldifference vs control (′D<0.05, ***o<0.001 (one wav ANOVA plus post hocBonferroni test) n=9.

Methods

Adult (200-250 g) male Wistar rats (Harlan Iberica, Spain) were used inall the experiments. The animals were housed in clear plastic cagesunder Standard laboratory conditions: controlled temperature 23±1° C.,12/12-h light/dark cycle and free access to food and water, Spontaneousbehaviour was observed in the cages before starting the experimentalprocedures, rats showing aggressiveness or alterations of the motilitywere discarded (2%). Number of animals per separated experimental groupwas at least 8.

Paclitaxel Induced Peripheral Neuropathy

After habituation to the test environment and baseline measurements ofpain sensitivity (see below), animals were i.p. Injected on fouralternate days (days 1, 3, 5 and 7) with paclitaxel (1 mg/kg), using eninjection volume of 1 ml/kg. The final cumulative paclitaxel doseadministered was 4.0 mg/kg (Polomano et al., 2001). The vehicle was amixture of saline and Cremophor EL 10%, a derivative of castor oil andethylene oxide. This vehicle is used clinically for paclitaxelinjections. Body weight was recorded (pre-treatment, and days 3, 5, 7,13, 10, 18, 22, 24 and 29 after the first paclitaxel or vehicleadministration) in the group of animals given paclitaxel (n=9) and inthose treated with vehicle (n=9).

Behavioral Assays

Heat Hyperalgesia and Mechanical Allodynia

The plantar surface of hind paws (sciatic nerve territory) was testedfar heat-hyperalgesia and tactile-allodynia and the vibrissal zone(trigeminal nerve territory) to evaluate the effect of theadministration of the different treatments.

Heat Hyperalgesia at Sciatic Nerve Territory (Hind Paw)

Heat-hyperalgesia of the hind paw was tested by measuring the latency(withdrawal time) of the hind paws from a focused beast of radiant heatapplied to the plantar surface using a plantar test apparatus (UgoBasile). Briefly, the rat was placed within a plastic compartment on aglass floor: a light source beneath the floor was aimed at the midplantar surface of the hind paw. The withdrawal reflex interrupts thelight and automatically turns off the light and a timer. The intensityof the light was adjusted at the Start of the experiment such that thecontrol average baseline latencies were about 8 sec and a cut-offlatency of 30 sec was imposed. The withdrawal latency of each paw wasmeasured during three trials at 2 min intervals and the mean of thethree readings was used for data analysis.

Tactile Allodynia at Sciatic Nerve Territory (Hind Paw)

Tactile allodynia was assessed by measuring the withdrawal threshold tocalibrated von Frey hairs with intensities ranging from 0.9 to 40 g.Filaments exerting a force above 40 g were not used as they lifted thepaws. On the day of the experiment animals were placed in a Perspexchamber with a mesh metal floor and allowed to acclimatize for 15 min.Starting with the lowest filament force, von Frey hairs were appliedperpendicular to the mid plantar surface of both hind paws, withsufficient force to cause slight bending against the paw, and held untila response was achieved, the mechanical Stimulation was maintained for 2seconds (maximum), this was repeated five times at an interval of 1-2 s.When the paw was sharply withdrawn, or when there was flinching uponremoval of the hair, a positive response was noted; when at least 3 outof 5 responses were positive (60%), this value was accepted as tactilethreshold. The process was repeated with the next higher force hair ifless than 3 positive responses were noted to any hair

Tactile Allodynia at Trigeminal Nerve Territory (Orofacial Region)

The effect of the paclitaxel administration in the trigeminal territoryhas not been previously studied. Paclitaxel was administered aspreviously described to test peripheral neuropathies on spinal nerves(Polomano et al., 2001).

The orofacial area was defined as the skin above the perioral (PO) skin.We measured the withdrawal threshold to calibrated von Frey hairs withintensities ranging from 0.9 to 40 g. A descending series of thefilaments were used when the rat responded to the starting filament.Each filament was tested five times at an interval of a few seconds. Ifhead withdrawal was observed at least three times after probing with afilament the rat was considered responsive to that filament. Theresponse threshold was defined as the lowest force of the filaments thatproduced at least three withdrawal responses in five tests.

Mechanical and thermal withdrawal thresholds were tested consecutivelyon the following groups of animals:

-   1. Control groups: a group injected with the paclitaxel vehicle (to    control handling effects). Tests were carried cut following the same    schedule as their corresponding treated groups.-   2. Paclitaxel treated animals: mechanical and thermal withdrawal    thresholds were tested before the administration of paclitaxel    (day 0) and on days: 3, 5, 7, 18, 21 and 22 after starting the    administration of paclitaxel. When an injection of paclitaxel had to    be given on the same day as behavioural testing, rate were injected    after the measurements had been taken.

After these procedures (day 22 after first administration of paclitaxel)rate received 3 μg/kg s.c.

Tests were carried out 30 min after i.p. or s.c. injection. Mechanicaland thermal withdrawal thresholds were tested in both paws in each groupin this sequence. Tactile allodynia in the orofacial were tested at theend of the experiment.

To assess if TTX was able to prevent or reduce the development ofnociceptive behaviours induced by paclitaxel, another procedure ofadministration was followed. Rate were simultaneously treated for oneweek with twice daily s.c. injections of TTX (3 μg/kg) and the usualprotocol of paclitaxel administration (see above). Nociceptivebehaviours were tested 3 weeks later.

3.1. Paclitaxel Induced Peripheral Neuropathy

As the effect of the repeated administration of paclitaxel onnociceptive behaviour has not boon previously evaluated on thetrigeminal territory, the first step was to compare the development ofallodynia in the perioral region with that recorded on the hind paw(sciatic territory). FIG. 6 shows the effect of paclitaxeladministration on orofacial allodynia and paw allodynia andhyperalgesia. Paclitaxel (1 mg/kg) significantly reduced the thermallatency and mechanical threshold when compared to the vehicle-treatedgroup (FIG. 8).

To evaluate the effect of acute TTX, tactile and thermal thresholds wereevaluated on days 0 (before paclitaxel), on day 21 (control of allodyniaand hyperalgesia induced by paclitaxel) and on day 22 after rats werei.p. injected with the drug.

Treatment with a single dose of TTX induced a partial but significantdecrease of the allodynia in the trigeminal and sciatic territories(FIGS. 7A y 7B).

TTX did nut significantly reduce this hyperalgesia, even though a slighttendency to do so can be seen.

Finally, the simultaneous treatment with paclitaxel and TTX was able toprevent the development of allodynia in the orofacial region and in thepaw as well as the hyperalgesia in the paw (FIG. 8).

EXAMPLES OF PHARMACEUTICAL COMPOSITIONS Orally AdministerableFormulations Example 1: Capsule Formulations

Example of a Formulation (A) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.03 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 98.47 mg Total 100 mg

Example of a Formulation (B) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.15 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 98.35 mg Total 100 mg

Example of a Formulation (C) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.3 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 98.2 mg Total 100 mg

Example of a Formulation (D) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.9 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 97.6 mg Total 100 mg

Example of a Formulation (E) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.25 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 98.25 mg Total 100 mg

Example of a Formulation (F) for a Capsule

Tetrodotoxin (TTX) (powdered material) 0.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 98.0 mg Total 100 mg

Example of a Formulation (G) for a Capsule

Tetrodotoxin (TTX) (powdered material) 1.0 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 97.5 mg Total 100 mg

Example of a Formulation (H) for a Capsule

Tetrodotoxin (TTX) (powdered material) 1.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Lactose 97.0 mg Total 100 mg

Example 2: Tablet Formulations

Example of a Formulation (A) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.03 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose93.47 mg Total 100 mg

Example of a Formulation (B) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.15 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose93.35 mg Total 100 mg

Example of a Formulation (C) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.3 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose93.2 mg Total 100 mg

Example of a Formulation (D) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.9 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose92.6 mg Total 100 mg

Example of a Formulation (E) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.25 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose93.25 mg Total 100 mg

Example of a Formulation (F) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose93.0 mg Total 100 mg

Example of a Formulation (G) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.0 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose92.5 mg Total 100 mg

Example of a Formulation (H) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg Sodium croscarmelose 5.0 mg Lactose92.0 mg Total 100 mg

Example 3: Additional Tablet Formulations

Example of a Formulation (A) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 0.03 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose68.47 mg Total 100 mg

Example of a Formulation (B) for a Tablet (Humid Granulation)

Tetrodetoxin (TTX) (powdered material) 0.15 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose68.35 mg Total 100 mg

Example of a Formulation (C) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 0.3 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose 68.2mg Total 100 mg

Example of a Formulation (D) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 0.9 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose 67.6mg Total 100 mg

Example of a Formulation (E) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 0.25 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose68.25 mg Total 100 mg

Example of a Formulation (F) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 0.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose 68.0mg Total 100 mg

Example of a Formulation (G) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 1.0 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose 67.5mg Total 100 mg

Example of a Formulation (H) for a Tablet (Humid Granulation)

Tetrodotoxin (TTX) (powdered material) 1.5 mg Colloidal silicon dioxide0.5 mg Magnesium stearate 1.0 mg POVIDONE K-30 5.0 mg Sodiumcarboxymethylstarch 5.0 mg Microcrystalline cellulose 20 mg Lactose 67.0mg Total 100 mg

Example 4: Additional Tablet Formulations

Example of a Formulation (A) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.03 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(AVICEL PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.97 mgTotal 800 mg

Example of a Formulation (B) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.06 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(AVICEL PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.94 mgTotal 800 mg

Example of a Formulation (C) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.12 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.88 mgTotal 800 mg

Example of a Formulation (D) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.18 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.82 mgTotal 800 mg

Example of a Formation (E) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.3 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.7 mgTotal 800 mg

Example of a Formulation (F) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.9 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.1 mgTotal 800 mg

Example of a Formulation (G) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.25 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.75 mgTotal 800 mg

Example of a Formulation (H) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.5 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.5 mgTotal 800 mg

Example of a Formulation (I) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.0 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 365.0 mgTotal 800 mg

Example of a Formulation (J) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.5 mg Sodium croscarmelose(AC-DI-SOL) 40 mg Colloidal silica dioxide (AEROSYL 200) 8 mg Magnesiumstearate, NF 16 mg POVIDONE K-30 40 mg Microcrystalline cellulose(Avicel PH-102) 346 mg Lactose monohydrate (FARMATOSE 200M) 364.5 mgTotal 800 mg

Example 5: Additional Tablet Formulations

Example of an Alternative Formulation (A) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.03 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.97 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (B) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.15 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.85 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (C) Tar a Tablet

Tetrodotoxin (TTX) (powdered material) 0.3 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.7 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (D) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.9 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.1 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (E) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.25 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.75 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (F) for a Tablet

Tetrodotoxin (TTX) (powdered material) 0.5 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.5 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (G) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.0 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 420.0 mgOPADRY II ® 24 mg Total 600 mg

Example of an Alternative Formulation (H) for a Tablet

Tetrodotoxin (TTX) (powdered material) 1.5 mg Sodium croscarmelose(AC-DI-SOL) 35 mg Colloidal silica dioxide (AEROSYL 200) 3 mg Sodiumstearate 12 mg Polyethylene glycol 8000 30 mg Microcrystalline cellulose(Avicel PH-102) 75 mg Lactose monohydrate (FARMATOSE 200M) 419.5 mgOPADRY II ® 24 mg Total 600 mg

Example 6: Additional Capsule Formulations

Example of an Alternative Formulation (A) of a Capsule

Tetrodotoxin 0.03 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 476.77 mg Total 480 mg

Example of En Alternative Formulation (B) of a Capsule

Tetrodotoxin 0.15 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 476.65 mg Total 480 mg

Example of an Alternative Formulation (C) of a Capsule

Tetrodotoxin 0.3 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 476.5 mg Total 480 mg

Example of an Alternative Formulation (D) of a Capsule

Tetrodotoxin 0.9 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 475.9 mg Total 480 mg

Example of an Alternative Formulation (E) of a Capsule

Tetrodotoxin 0.25 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 476.55 mg Total 480 mg

Example of an Alternative Formulation (F) of a Capsule

Tetrodotoxin 0.5 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 476.3 mg Total 480 mg

Example of an Alternative Formulation (G) of a Capsule

Tetrodotoxin 1.0 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 475.8 mg Total 480 mg

Example of an Alternative Formulation (H) of a Capsule

Tetrodotoxin 1.5 mg Colloidal silica dioxide 0.8 mg Magnesium stearate2.4 mg Lactose 475.3 mg Total 480 mg

Example 7: Outwardly Solid Formulations

Encapsulated Outwardly Solid Formulation (A)

Tetrodotoxin 60 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (B):

Tetrodotoxin 300 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (C)

Tetrodotoxin 600 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (D)

Tetrodotoxin 1800 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (E)

Tetrodotoxin 500 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (F)

Tetrodotoxin 1000 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (G)

Tetrodotoxin 2000 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Encapsulated Outwardly Solid Formulation (H)

Tetrodotoxin 3000 mg 0.5% dilute acetic acid 1 ml Acetic Acid-acetatebuffer 50 ml (5% of the total volume of the solution (pH = 3.5) preparedpharmaceutical solution) Water, sterile, add to 1000 ml

0.5 ml of this prepared solution were encapsulated in suitableconsumable capsules and stored.

Example 8

Example of a Further Alternative Formulation of a Tablet Ready to beProcessed into an Enteric-Coated Formulation

Tetrodotoxin 0.5 mg Dibasic Calcium Phosphate USP 46.8 mg Avicel PH 10150.0 mg NATROSOL 250 HHX 1.0 mg CAB-O-SIL M5 0.5 mg Magnesium StearateNF 1.0 mg Yellow Lake F D & C No 6 0.2 mg Purified Water USP (evaporatesduring the process) Total 100 mg

Example 9

Example of an Enteric-Coated Version of Example 8

Tablet according to Example 8  100 mg Acryl-Eze yellow coatingsuspension House Std 40.0 mg

Example 10

Example of Another Form of Tablet Ready to be Processed into a CoatedControlled-Release Formulation

Tetrodotoxin 0.5 mg Dibasic Calcium Phosphate USP 40.0 mg Avicel PH 10146.8 mg NATROSOL 250 HHX 10.0 mg CAB-O-SIL M5 0.5 mg Magnesium StearateNF 2.0 mg Blue F D & C No1 0.2 mg Purified Water USP (evaporates duringthe process) Total 100 mg

Example 11

Example of a Coated Controlled-Release Version of Example 10

Tablet according to Example 10  100 mg SURETERIC Blue suspension HouseStd 20.0 mg 90/10 SURELEASE/OPADRY clear suspension 30.0 mg

Example 12

Example of a Further Alternative Formulation of a Tablet Ready to beProcessed into a Coated Formulation

Tetrodotoxin 0.5 mg Dibasic Calcium Phosphate USP 46.0 mg Avicel PH 10150.0 mg AC-DI-SOL 2.0 mg CAS-O-SIL M5 0.5 mg Magnesium Stearate NF 1.0mg Purified Water USP (evaporates during the process) Total 100 mg

Example 13

Example of a Coated Version of Example 12

Tablet according to Example 12  100 mg OPADRY II coating suspensionHouse Std 20.0 mg

Example 14

Example of a Further Alternative Formulation of a Tablet Ready to beProcessed into an Enteric-Coated Formulation

Tetrodotoxin 1.0 mg Dibasic Calcium Phosphate USP 46.3 mg Avicel PH 10150.0 mg NATROSOL 250 HHX 1.0 mg CAB-O-SIL M5 0.5 mg Magnesium StearateNF 1.0 mg Yellow Lake F D & C No 6 0.2 mg Purified Water USP (evaporatesduring the process) Total 100 mg

Example 15

Example of an Enteric-Coated Version of Example 14

Tablet according to Example 14  100 mg Acryl-Eze yellow coatingsuspension House Std 40.0 mg

Example 16

Example of Another Form of Tablet Ready to be Processed into a CoatedControlled-Release Formulation

Tetrodotoxin 1.0 mg Dibasic Calcium Phosphate USP 40.0 mg Avicel PH 10146.3 mg NATROSOL 250 HHX 10.0 mg CAB-O-SIL M5 0.5 mg Magnesium StearateNF 2.0 mg Blue F D & C No1 0.2 mg Purified Water USP (evaporates duringthe process) Total 100 mg

Example 17

Example of a Coated Controlled-Release Version of Example 16

Tablet according to Example 16  100 mg SURETERIC Blue suspension HouseStd 20.0 mg 90/10 SURELEASE/OPADRY clear suspension 30.0 mg

Example 18

Example of a Further Alternative Formulation of a Tablet Ready to beProcessed into a Coated Formulation

Tetrodotoxin 1.0 mg Dibasic Calcium Phosphate USP 45.5 mg Avicel PH 10150.0 mg AC-DI-SOL 2.0 mg CAB-O-SIL M5 0.5 mg Magnesium Stearate NF 1.0mg Purified Water USP (evaporates during the process) Total 100 mg

Example 19

Example of a Coated Version of Example 18

Tablet according to Example 18  100 mg OPADRY II coating suspensionHouse Std 20.0 mg

With the guidance provided herein, once the required parameters of acomposition or method are known, those skilled in the art MI be readilyable to determine the amounts and proportions of active components andother components required to manufacture a required dosage form,manufacture a kit or composition, or use the methods and compositionsdisclosed. The foregoing embodiments have been described in detail byway of illustration and example for purposes of clarity andunderstanding. As is readily apparent to one skilled in the art, theforegoing are only some of the methods and compositions that illustratethe possible embodiments. It will be apparent to those of ordinary skillin the art that a range of equivalents, variations, changes,modifications and alterations may be applied to the compositions andmethods described herein without departing from the true spirit, conceptand scope of the invention.

The invention claimed is:
 1. A method for the treatment of neuropathicpain which has developed as a consequence of chemotherapy with achemotherapeutic agent, the method comprising: administering viasubcutaneous injection a unit dose in the range of about 5 μg to about2000 μs of one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof, to a subject suffering fromneuropathic pain which has developed as a consequence of chemotherapywith the chemotherapeutic agent; and continuing treatment with thechemotherapeutic agent by administering the chemotherapeutic agent. 2.The method of claim 1, wherein the one or more of tetrodotoxin, ananalog, derivative, or pharmaceutically acceptable salt thereof isselected from the group consisting of tetrodotoxin,anhydro-tetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin,ethoxytetrodotoxin, deoxytetrodotoxin, tetrodonic acid,11-galactopyranosyl-tetrodotoxin, 4-olefinic-tetrodotoxin,4-epi-tetrodotoxin, 6 epi-tetrodotoxin, 11-deoxytetrodotoxin,hemilactals of tetrodotoxin, lactones of tetrodotoxin, 4,9-anhydrotetrodotoxin, and combinations thereof.
 3. The method of claim 1,wherein the one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof is administered in an amount inthe range from 5 μg/day to 4000 μg/day.
 4. The method of claim 1,wherein the one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof is administered in an amount inthe range from 0.1 μg/kg/day and 40 μg/kg/day.
 5. The method of claim 1,wherein the one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof is administered daily in twodoses.
 6. The method of 5, wherein each dose is in an amount of between5 μg and 2000 μg.
 7. The method of claim 1, wherein the one or more oftetrodotoxin, an analog, derivative, or pharmaceutically acceptable saltthereof is isolated from a biological source.
 8. The method of claim 1,wherein the one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof is synthetic.
 9. The method ofclaim 1, wherein the unit dose is in the range of 5 μg to about 150 μg.10. The method of claim 9, wherein the chemotherapeutic agent isselected from the group consisting of a platinum derivative, a vincaalkaloid, a taxane, cisplatin, carboplatin, oxaliplatin, vincristine,vinblastine, vinorelbine, vindesine, paclitaxel, docetaxel, andcombinations thereof.
 11. A method for the treatment of neuropathic painwhich has developed as a consequence of chemotherapy comprising:administering via subcutaneous injection a unit dose in the range of 5μg to 500 μg of one or more of tetrodotoxin, an analog, derivative, orpharmaceutically acceptable salt thereof, to a subject suffering fromneuropathic pain which has developed as a consequence of chemotherapy.12. The method of claim 1, wherein the neuropathic pain is peripheralneuropathy, allodynia or hyperalgesia.
 13. The method of claim 11,wherein the neuropathic pain is peripheral neuropathy, allodynia orhyperalgesia.